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Recent events in the Middle East focused
attention on the renewed threat of chemi-
cal warfare. The relative ease of warfare
agent production from readily available
industrial chemicals, the documented use
ofchemical weapons by Iraq against Kurd-
ish civilians and Iranian military personnel
(1-3), and the widespread possession of
such weapons, raises the issue of chemical
warfare proliferation to other conflicts (4)
or to terrorist activity. Domestic attention
to chemical munitions has also been
sparked by the congressional mandate to
destroy the U.S. unitary stockpile via
incineration (PL 99-145 and PL 100-456);
congressional directives to examine safe
disposal of nonstockpile chemical material
thought to be present in 32 states, the
District of Columbia, and the Virgin
Islands (PL 102-484; 5); and the January
1993 signing of the Chemical Weapons
Convention banning the manufacture, use,
stockpiling, and transfer of chemical
weapons (6).
The Chemical Stockpile Disposal Pro-
gram (CSDP) ofthe U. S. Army will carry
out the intent of Congress regarding the
unitary stockpile; details are provided in
the CSDP-Final Programmatic Environ-
mental Impact Statement (FPEIS), (7) and
summarized by Carnes (8) and Carnes and
Watson (9). Workplans, budgets, and deci-
sion criteria for nonstockpile agents and
munitions are currently under develop-
ment (5).
Two nerve agents [GB (sarin), methyl-
phosphonofluoridate isopropyl ester and
VX, S-(diisopropylaminoethyl) methyl-
phosphonothiolate o-ethyl ester], are stock-
piled at six continental U. S. military
installations. These installations include
Anniston Army Depot (ANAD), near
Anniston, Alabama; Blue Grass Army
Depot (BGAD), near Richmond, Ken-
tucky; Newport Army Ammunition Plant
(NAAP), near Newport, Indiana; Pine
Bluff Arsenal (PBA), near Pine Bluff,
Arkansas; Tooele Army Depot (TEAD),
near Tooele, Utah; and Umatilla Depot
Activity (UMDA), near Umatilla, Oregon
(see Table 1 for location of individual
agent stockpiles) (7). A third nerve agent,
GA (tabun; N.N-dimethyl phosphoroami-
docyanidate ethyl ester), is present in small
quantities only at TEAD (7,10). Physical
and chemical characteristics ofthese agents
are presented in Table 1 and their chemical
structures are shown in Figure 1.
Organophosphate (OP) nerve agents
were designed specifically to cause incapaci-
tation or death in military use and are par-
ticularly effective because oftheir extremely
high acute toxicity. This acute toxicity is
three to four orders of magnitude greater
than most ofthe chemically similar OP pes-
ticides, whose acute toxicological endpoints
are much the same (15). The probability of
an inadvertent release with off-site conse-
quences during current storage or any dis-
posal alternative considered in the CSDP-
FPEIS is extremely low, being estimated to
range from 1 in 10-4 to 1 in 10-10 (7,9). A
credible risk, for purposes of CSDP plan-
ning, is conservatively considered to be one
with a probability ofone in 100 million or
greater (2 10-8) (16). Some of the release
scenarios considered in the CSDP-FPEIS
include exposure ofArmy personnel and a
few extend to off-site populations. Effects
on individuals could range from none to life
threatening, depending on factors such as
the type and concentration of agent re-
leased, the duration ofexposure, individual
variations in sensitivity, and the availability
of antidotes, decontamination, and treat-
ment capability. Some low-probability sce-
narios could result in catastrophic aggregate
effects (i.e., > 1000 fatalities). One alterna-
tive considered, and rejected in the FPEIS,
was continued storage of the agents for 25
years. This option is estimated to entail a
higher number of potential fatalities from
credible accidents than on-site disposal (17).
An analysis ofthe toxicity ofeach nerve
agent in the stockpile was performed as part
ofevaluating the on- or off-site destruction
options (7). Watson et al. (18) and Carnes
and Watson (9) summarized the results of
that analysis. This review is the third in a
series of articles in EHP addressing health
effects issues related to stockpile destruction.
In the first, Munro et al. (10) evaluated
nerve and vesicant agent antidotes, deconta-
mination procedures, and treatment proto-
cols for use in a civilian context. In the sec-
ond, Watson and Griffin (19) detailed the
toxicity of vesicant agents, with particular
attention to mustard agent carcinogenicity.
The present review documents essential
information on nerve agent toxicity that is
useful to civilian medical personnel and
emergency planners involved in preparation
forstockpile disposal at each community.
We first review briefly the general fea-
tures of the nerve agents, signs and symp-
toms ofexposure and mechanism ofaction,
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biochemical indicators of exposure, and
metabolism. We then present indices of
acute toxicity ofthe nerve agents alone and
in combination, followed by information
on potential delayed and persistent effects
ofacute exposure. These endpoints include
delayed neuropathy, psychological and
EEG changes, and cardiac effects. We next
review results ofstudies on chronic or sub-
chronic systemic toxicity, carcinogenicity,
genotoxicity, teratogenicity, and reproduc-
tive toxicity. Finally, we discuss the impli-
cations of the varied acute toxic effects of
nerve agent exposure for protection of the
general public, as well as emergency and
medical personnel.
General Features and
Mechanism of Nerve Agent
Action
According to Harris and Paxton (20), GA,
or tabun, was the first nerve agent devel-
oped for chemical warfare; it was discov-
ered in late 1936 and produced in large
scale by 1942 (20,21). Subsequent G
agents such as GB are both more toxic
than GA and also more resistant to hydrol-
ysis. GA contains cyanide instead of fluo-
ride (see Fig. 1). It is more volatile than
VX (see Table 1). Agent GA is stored in
relatively small quantities in bulk at only
one rather remote continental U. S. site
(TEAD) (Table 1). Thus, concerns about
public health hazards presented by GA in
the course of the CSDP are relatively
minor compared with those of GB and
VX.
Because ofits volatility, GA is primari-
ly an inhalation hazard; it tends to disperse
rapidly and is not likely to be a contact or
ingestion hazard. However, GA is less
Figure 1. Molecular structures of the OP nerve agents GA, GB, and VX [adapted from Dacre (13) and
Gordon etal. (14)].
volatile than GB (Table 1) and would be
expected to remain on the skin and in the
environment somewhat longer. Although
it is not as persistent as VX, under certain
weather conditions (light breeze, 20'C or
680F) GA can remain in the environment
from 1 to 4 days (22). Agent GA differs
from other G nerve agents in some of its
biochemical effects on the brains of ex-
posed animals and also in the rarity ofGA-
induced convulsions, even at lethal doses
(23).
Agent GB, or sarin, a fluorine-contain-
ing OP (Fig. 1), is the most studied ofthe
three nerve agents considered in this analy-
sis. Because of its high volatility and
expected rapid dispersion, GB is the agent
of greatest concern for acute inhalation
exposures in an unplanned release at those
sites housing it (ANAD, BGAD, PBA,
TEAD, and UMDA; Table 1). Because of
its high volatility, GB is not a great con-
cern from the standpoint of reentry to a
previously contaminated area. GB is some-
what less effective as a skin penetrant than
as an inhalant because it evaporates so
rapidly from the skin.
Agent VX, a sulfur-containing OP
(Fig. 1), is, by any route of exposure, the
most potent of all the nerve agents dis-
cussed here (Table 2). When compared to
the G agents, VX is more stable, more
resistant to detoxification, less volatile,
more efficient at skin penetration, and
Table 1. Chemical and physical properties, location, andtype ofchemical munitions (11,12)
Chemical name
Chemical formula
Chemical abstract no.
Molecularweight
Description
Melting point, TC
Boiling point, TC
Density (liquid, g/mL, 251C)
Volatility (mg/m3, 250C)
Solubility, water(g/l)
Solubility, other
Storage location8
Munitiontypeb
GA,tabun
Ethyl-N, N-dimethyl
phosphoramidocyanidate
C5HJJN202P
77-81-6
162.1
Colorless, odorless liquid
-50
245
1.08
610
98 (250C) (miscible)
Very soluble in mostorganic solvents
TEAD
TC
GB, sarin
Isopropyl methyl
phosphonofluoridate
C4HiOF02P
107-44-8
140.1
Colorless, odorless liquid
-56
158
1.09
2.2x104
Miscible
Readily soluble in organic solvents
ANAD, BGAD, PBA, TEAD, UMDA
P. R, B, C,TC
Vx
O-ethyl-S-(2-diisopropyl aminoethyl)
methyl phosphonothiolate
C11H26N02PS
50782-69-9
267.4
Colorless, odorless liquid
-39(calculated)
298
1.0083
10.5
30(250C)
75(150C)
(miscible d9.40C)
Readily soluble in organic solvents
ANAD, BGAD, NAAP, PBA,
TEAD, UMDA
P, R, M, ST,TC
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qTEAD, Tooele Army Depot; ANAD,Anniston Army Depot; BGAD, Blue Grass Army Depot; PBA, Pine BluffArsenal; UMDA, Umatilla DepotActivity; NAAP,
NewportArmyAmmunition Plant.
bB, bombs; C, cartridges; M, mines, P, projectiles; R, rockets, S, shells; ST, spraytanks; TC, ton containers.
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more environmentally persistent. Because
of these characteristics, VX is more effec-
tive as a skin penetrant and lethal contact
agent rather than as an inhalation threat.
Signs and Symptoms of
Exposure
The nerve agents are among the most
potent of all chemical warfare agents and
are highly toxic in both liquid and vapor
form. In vapor or aerosol form, nerve
agents can be inhaled or absorbed through
the skin or the conjunctiva ofthe eye; as a
liquid, they can be absorbed through the
skin, conjunctiva, and upper gastrointesti-
nal tract (38). Because they are essentially
colorless, odorless, tasteless, and nonirritat-
ing to the skin, their entry into the body
may not be perceived by the individual
until grave signs and symptoms appear.
Within seconds after exposure to low
levels of nerve agent vapor, local effects
may be observed in the eyes and the respi-
ratory system of humans. Depending on
the agent and the dosage, the local ocular
effects may be a constriction of the pupils
ofthe eye (miosis) lasting only several days
or a prolonged miosis persisting for many
weeks (39,40), pain, and/or dim vision
(29). Respiratory effects may include bron-
choconstriction, excess secretion in air-
ways, wheezing, and labored breathing
(25p. The time of onset of moderate sys-
temic effects depends in part on the route
of exposure; it is within seconds to a
minute or two after inhalation, within 45
Table2. Acute toxic levels of nerve agents
Exposure route GA GB VX VX (aerosol)
Inhalation,LCt50 (mg-min/m3)
Human, mild activity (estimated)
Human, resting (estimated)
Monkey
Dog
Rabbit
Guinea pig
Rat
Mouse
Dermal, airborne LCtso(mg-min/m3)
Human, clothed (estimated)
Human, bare skin (estimated)
Dog, clipped
Rabbit, clipped
Rabbit, clipped and clothed
Dermal, liquid LD50 (mg/kg)
Human (estimated)
Monkey, shaved
Pig, clipped
Dog, depilated
Cat, depilated
Rabbit, depilated
Rat, depilated
Mouse, depilated
Intravenous LD50 (mg/kg)
Human (estimated)
Monkey
Goat
Dog
Cat
Rabbit
Rat
Mouse
Oral LD50 (mg/kg)
Rat
Incapacitating dose, ICt50 (mg-min/m3)
Human, inhalation, mild activity (estimated)
Human, inhalation, resting (estimated)
Human, percutaneous, clothed (estimated)
Effective dose-miosis, ECt50(mg-min/m3)
Human, inhalation (estimated)
Effective dose-tremors, ECt50(mp-min/m3)
Human, inhalation (estimated) (25)
Effective dose-GI signs,ED5 (mg/kg)
Human, bare skin, 18-241C (estimated)
No-effects dose-miosis (mg-min/m3)
Human, inhalation (estimated)
No-effects dose-tremors (mg-m/in/m3)
135-150(11,21)
200-400 (11,22)
187(11)
320 (11)
960(11)
450(11)
-20,000-40,000(11,22)
14-21 (27)
9.3(11)
-45 (11)
3(11)
12.6(11)
0.014(21)
-0.05(11)
0.084(11)
0.063(11)
0.07 (11)
0.311(34)
1.06(11)
100.(22)
300 (26)
0.9(11)
70(11)
100(11,22,25)
74(11)
60(11)
120(11)
180(11)
220(11)
240,310 (11)
15,000 (11)
12,000(11)
2,000(11)
24(11)
115.9(11)
10.8(11)
6.2(11)
4.4(11)
2.5(11)
1-9.2(11,31)
0.014(11)
0.020(11)
0.015(11)
0.010(11)
0.015-0.018 (11,32)
0.0147 (33)
0.045(11)
0.07-0.113(34-36)
30(11)
36(22)
-50(11)
15a(11)
17a(11)
40(11)
60,3,600e(11)
6,360e(11)
4.6,89g(11)
8.3, 28 (11)
539'(26)
0.04(28),0.14(29)
-0.065 (11)
<0.40(11)
0.054 (11)
0.012(11)
0.025,0.205 (30)
0.10(11)
0.046 (11)
0.008 (11)
0.0084(11)
<0.005 (11)
0.0063 (11)
-0.0025 (11)
0.0084 (11,28)
0.0079 (11)
0.0141 (11)
0.10(11)
35-72(11,22,27)
75(27)
8,000(11)
2-4(25)
28(25)
0.5 (25)
4.0 (25)
24(11)
0.09(37)
1.6 (36)
0.0314(11)
0.02 (37)
8Only head exposed.
bWind speed 0.01 mph.
CWind speed 15 and 0 mph, respectively.
dActive, resting, respectively.
"Masked, wind speed 15 and 1 mph, respectively.
"Masked, wind speed 10 and 0 mph and particle size 15, 5 pm, respectively.
-Wind speed 20 and 0 mph, respectively.
1Wind speed 15 and 5 mph, respectively.
Wind speed 8 and 0mph, respectively.
'Clothed in cotton sateen over cotton t-shirt.
kBare, clipped; and clothed, unclipped, respectively.
fCalculated fromLCt5WECt5= 2.5 at 15 I/min-breathing rate
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20-50 (24)
25ab(11)
8, 308c(fl)
7 (11)
75,300'(24)
3.5,31.8 (11)
124,180(11)
5-15 (24)
30-150 (24)
20min after ingestion, and within 2-18 hr
after application on the skin (38,41).
Exposure to lethal doses, however, can lead
to collapse within seconds and death with-
in 10 min after a single deep inhalation
(21). After short-term (acute) exposure,
mild systemic effects may last for several
hours to days, whereas moderately severe
symptoms can last for 1-6 days. During
the recovery period, symptoms may recur
intermittently, particularly after physical
exertion (38).
The toxic actions of nerve agents are
due primarily to their ability to inhibit
acetylcholinesterase (AChE), an enzyme
responsible for the breakdown of the neu-
rotransmitter acetylcholine (ACh). The
result is excessive ACh accumulation at
synapses, where only minute quantities of
ACh are needed for transmission. Acetyl-
choline overstimulation of the portions of
the nervous system that control smooth
muscle, cardiac muscle, and exocrine glan-
dular function results in the following
signs: drooling, increased bronchial secre-
tions, bronchoconstriction, miosis, exces-
sive sweating, vomiting, diarrhea, abdomi-
nal cramping, involuntary urination, and
cardiac arrhythmias. In addition, ACh
overstimulation ofthe central nervous sys-
tem (CNS) may result in headache, anxi-
ety, restlessness, irritability, giddiness,
insomnia, nightmares, EEG changes, or
even convulsions and coma, depending on
the agent and the dosage (38). Finally,
ACh accumulation affects the nerves con-
trolling skeletal muscle, resulting in a dose-
dependent generalized weakness that
increases with exertion, as well as muscle
twitching and fasciculation, cramping, and
even flaccid paralysis.
Respiratory failure, the immediate
cause of death in nerve agent exposure, is
an example of an effect that occurs as the
result ofACh accumulation at several sites
in the nervous system. Depression of the
brain's respiratory center, neuromuscular
block ofthe respiratory muscles, bronchial
constriction, and increased lung secretions
are all factors contributing to nerve agent-
induced respiratory failure; the relative
importance ofeach depends on the species
studied, the nerve agent, and the dosage
used (42-48).
Recent interest has developed in the
acute behavioral toxicity of nerve agents.
In this relatively new field ofinvestigation,
animals are tested for changes in motor
and learning behavior after exposure to the
compound of interest. Karczmar (49) has
listed the CNS effects, including behav-
ioral and mental health effects, that have
been observed with several anticholin-
esterase chemicals. To date, the number of
these effects that can be ascribed to nerve
agent exposure is limited. In most cases,
motor effects in animals appeared at levels
ofexposure that caused mild (some saliva-
tion, fine tremors) to moderate (excessive
salivation and weeping, generalized trem-
ors) toxic effects (36,50-54). However,
some animal tests indicate acute effects on
learning behavior at exposure levels below
those that cause signs of nerve agent poi-
soning (51,53). Results of such studies
must be interpreted with much caution
(55). Applicability to humans is suggested
by preliminary work in volunteers exposed
to VX, demonstrating that performance on
a number facility test was impaired to a
statistically significant extent (p < 0.01) in
conjunction with minimal or absent physi-
cal signs and symptoms (56).
Mild to severe human exposures to nerve
agents have been associated with other men-
tal and emotional effects. These range from
giddiness and loss of ability to concentrate
through anxiety, tension, and irritability, to
withdrawal, depression, insomnia, and
nightmares (56,5X. Such effects and associ-
ated EEG changes were experienced in con-
cert with the onset of nausea and other
symptoms in the case ofGB, orearlier in the
case of VX. Some mental and emotional
effects may persist for hours, days, or weeks,
dependingpartlyon theseverityofexposure.
Agent-induced ACh accumulation gen-
erates side effects that involve action on
other CNS neurotransmitter systems (e.g.,
norepinephrine, dopamine, y-aminobutyric
acid). Numerous biological effects result
(58-61) including hypothermia in rats
(61,62), prolonged analgesia in mice (63),
and brain and cardiac lesions in animals sur-
viving high doses of nerve agents (64,65).
The interplay of the various neurotransmit-
ters within the nervous system probably
results in these varied side effects (45,66),
although nerve agents may exert direct
effects on these same noncholinergic systems
(67-69).
Biochemical Indicators of
Nerve Agent Exposure
Despite new knowledge derived in animals
as to the novel cholinergic and noncholiner-
gic effects of nerve agents and related
organophosphates, it is still widely accepted
that inhibition ofAChE is the primary cause
ofacute toxic responses to nerve agent expo-
sure in humans. For this reason, attempts
have been made to measure blood cholin-
esterase (ChE) activity as an indicator ofthe
magnitude of nerve agent exposure and/or
the severity ofclinical signs and symptoms
or to monitor the return ofblood ChE func-
tion as an indexofrecovery. Only in the case
ofsystemic effects is there a reasonably good
correlation with the degree of ChE inhibi-
tion.
Two types ofChE activity can be mea-
sured in blood, red blood cell AChE
(RBC-ChE), and nonspecific plasma ChE
(butyryl ChE or pseudocholinesterese).
Systemic effects are seen in about 50% of
exposed volunteers when RBC-ChE is
20-25% of normal baseline (a depression
of75-80%) (56,57,70-72). Monitoring of
RBC-ChE activity is theoretically preferred
because this cholinesterase is similar to the
AChE found at the nerve synapses. RBC-
ChE, however, is replenished onlywith the
formation ofnew RBCs in the case ofGB
(57), while it spontaneously reactivates
(1% per hour) in the case of VX (54).
Furthermore, recovery offunction or cessa-
tion of signs and symptoms occurs well
before RBC-ChE levels show much recov-
ery, especially after GB exposure (57).
Thus, recovery of RBC-ChE activity does
not reflect the time course of recovery of
AChE activity in the tissues. As a result,
monitoring of RBC-ChE activity is of
questionable utility in assessing recovery
from nerve agent (particularly GB) expo-
sure in individuals for whom baseline
RBC-ChE values are unavailable (see
below) (71).
Plasma ChE measurement is less rele-
vant than RBC-ChE activity; the inhibi-
tion ofplasma ChE, which has no known
biological function, may not reflect actual
AChE inhibition (73). For example, agent
VX causes significantly less inhibition of
plasma ChE than AChE (57,72,74). Agent
GB also preferentially inhibits RBC-ChE
(75), although not to the same extent as
VX. Furthermore, plasma ChE is more
labile than RBC-ChE, being affected by
gender, age, and oral contraceptive use
(76), as well as genetic determinants, dis-
ease states, nutritional status, hormonal
changes, race, and circadian patterns
(77,78). Plasma and RBC-ChE do serve a
protective function, complexing with nerve
agent and thus reducing the concentration
of free nerve agent available to complex
with tissueAChE (Fig. 2).
Because ofthe variability ofblood ChE
activity (both plasma and RBC) in unex-
posed individuals, it is difficult to deter-
mine conclusively from a single test wheth-
er a person has had a recent exposure to a
cholinesterase inhibitor, especially if the
exposure is minor (79,80). Yager et al. (81)
found the RBC-ChE intraindividual coef-
ficient ofvariation to be 10.0% and that of
plasma ChE to be 14.4%. With one prior
measurement of baseline ChE activity in
an individual, a 15% RBC-ChE depression
is the least that can be reliably detected
compared to a 20% decrease from baseline
for plasma ChE (80) (Table 3). When
individual baseline blood AChE activity is
known and is compared with the post-
exposure activity level, a dose-dependent
relationship can be demonstrated between
AChE inhibition and dosage at a limited
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-1 -.1 11"JIM mFigure 2. Plasma and RBC-cholinesterase (ChE) provide a bufferto neurotoxic action by completing with
nerve agent, thus reducing the concentration of free nerve agent available to move into tissue compart-
ments and inactivate synaptic or myoneural acetylcholinesterase (AChE). PChE, plasma cholinesterase;
NA, nerve agent; NS, nervous system.
range of acute sublethal doses (56,5/).
Doses of GB and VX required to depress
human RBC-ChE activities by 50%
(ChE50) are presented in Table 4. Brain
AChE inhibition and the degree oftoxici-
ty show a better correlation in that GA
and GB injected into rats produced a
dose-dependent inhibition ofbrain AChE,
with lethal doses producing > 90% inhibi-
tion (61). Although brain AChE activity
may reflect the dose response to nerve
agent exposure more closely than blood
AChE, human brain AChE monitoring
can be done only in an invasive manner
and thus has no practical application in
assessing human exposure.
Metabolism
The detoxification or breakdown of GA
within the body proceeds at a low rate
(2X), by way of the enzyme diisopropyl-
fluorophosphatase (formerly termed tab-
unase), which has been identified in sever-
Table 3. Minimal differences required for recog-
nition of statistically significant depression of
individual human plasma and red cell cholin-
esterase activityvalues"
No.of
preexposure % Difference from baseline
estimations Plasma Cells
1 19.9 15.3
2 17.3 13.3
3 16.3 12.5
4 15.7 12.1
5 15.5 11.9
10 14.7 11.3
00 14.1 10.9
'Adapted from Callaway etal.(80),with permission.
al species including man (83). Agent GB is
detoxified in certain animal species by the
plasma enzyme carboxylesterase, formerly
called aliesterase. Carboxylesterase com-
bines rapidly with GB and prevents it
from interacting with AChE. In rats, 10
min after intravenous (IV) injection of
radiolabeled GB, approximately 70% of
the plasma activity was bound to large
protein molecules identical to carboxyl-
esterase (84). Pretreatment ofrats with tri-
orthocresylphosphate (TOCP), a weakly
anti-ChE organophosphorus compound
that irreversibly blocks carboxylesterase,
resulted in a six- to eightfold enhancement
of GB toxicity (85). Additionally, more
GB was found in the brain, muscles, kid-
neys, and lungs and less GB in the plasma
ofTOCP-pretreated rats as compared to
rats that received no pretreatment. Similar
carboxylesterase modification ofGB toxic-
ity has been observed in guinea pigs and
mice, although guinea pig plasma car-
boxylesterase binding capacity for GB is
lower than that ofrat plasma (86,87). The
presence of carboxylesterase in rodent
plasma may by itself account for the rela-
tive resistance ofmice and rats to GB toxi-
city compared with other animal species
(see Table 2 for LD50 values). Human
plasma does not contain carboxylesterase.
Grob and Harvey (57) calculated that
there is very little detoxification when GB
is injected into the human bloodstream.
This major difference in the detoxification
ofGB between rodents and humans high-
lights the uncertainty ofestimating human
LD50 values from data obtained for
rodents.
Metabolism studies of GB have been
carried out in dogs and mice. Metabolism
studies in dogs demonstrated that the near-
lyexclusive product ofGB detoxification is
isopropyl methylphosphonic acid (88).
This compound accounted for the majori-
ty ofGB activity found not only in plasma
and urine, but also in brain tissue, suggest-
ing that brain, like a variety oftissues from
several mammalian species, can hydrolyze
GB (88). A rapid hydrolysis of intra-
venously injected GB occurred in mice,
such that less than 10% of the GB found
in the tissues was nonhydrolyzed within 1
min (36). This rapid hydrolysis ofGB may
be again due to plasma AE, but this hy-
pothesis has not been established. A ques-
tion remains as to the relevance ofextrapo-
lating to humans from any metabolism
studies using a species (mouse) that is resis-
tant to the toxiceffects ofGB.
Acute Toxicity
Because human exposure data are not
available on the lethal doses of the nerve
agents discussed here, animal toxicity data
have historically been extrapolated to
develop human dose estimates. The dose
or exposure levels ofGA, GB, and VX that
result in 50% lethality (LD50, LCt50) in
several species by various routes of expo-
sure are presented in Table 2. The route of
exposure is important because there are
differences in absorption and/or degrada-
tion with different avenues of entry into
the body. Although the IV route is not rel-
evant to accidental exposure ofman, inclu-
sion ofthese data in Table 2 illustrates the
intrinsic toxicity of the agents without
individual or species variations in absorp-
tion and is useful for comparison. Table 2
also includes estimates of doses, based on
animal data, that could cause 50% mortali-
ty in human populations exposed by some
of these same routes. Comparisons be-
tween species (particularly comparisons of
animal data with human estimates) are
possible since the LD50 values (or the esti-
mated values) are given on a milligram of
agent administered per kilogram of body
weight (mg/kg) basis. Table 2 also contains
the estimated human median incapacitat-
ing concentration-time product (ICt50),
effective dose or concentration-time prod-
uct (ED50, ECt50) [also termed minimum
effective dose in the U. S. Army Chemical
Agent Data Sheets (11)], and no-effects
dose for each nerve agent. Unfortunately,
the source document (9) does not define
what is meant by incapacitation.
Agent GA
As mentioned previously, the human doses
for lethality (LD50) or incapacitation
(ICt50) provided in Table 2 are merely esti-
mates (11,22). This is evident in a compar-
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ison of the inhalation incapacitating Ct
product (ICt50) of 300 mg-min/m3 and
the range of 200-400 mg-min/m3 for the
lethal dose (LCt50) for GA in resting
humans (breathing 10 1/min); the incapaci-
tating dose falls within the range for the
lethal dose. The degree of incapacitation
associated with this dose is not defined in
the source (11), but likely is severe, mean-
ing unconscious and convulsing.
Agent GB
GB is a very rapidly acting toxicant; there
is little difference between the 15-min and
the 24-hr lethal dose for animals by IV
injection (Table 2) (28). GB has been
thought by some to act primarily on the
peripheral nervous system; however, respi-
ratory arrest induced in cats by an IV dose
equivalent to one-halfthe feline LD50 (48)
was mediated through effects on the cen-
tral nervous system. GB is very efficient at
producing central respiratory arrest in
guinea pigs and cats at IV doses too low to
cause an effect on the respiratory muscles
(32). Thus, the primary effects of GB
appear to be on the CNS.
Like all other nerve agents, GB com-
bines with and inhibits AChE, resulting in
the accumulation ofACh. From studies in
which small quantities ofGB were injected
directly into the bloodstream of human
volunteers, Grob and Harvey (57) calculat-
ed that about 75% of GB combined with
AChE in the muscle, about 22% with
blood ChE, and about 3% with AChE in
brain and liver. The inhibition of blood
ChE results in no toxic effect; rather, it is
the GB inhibition of brain and muscle
AChE that causes the symptoms of nerve
agent exposure. Within the muscles ofcats,
GB caused a dose-dependent inhibition of
AChE activity; however, no simple rela-
tionship existed between AChE inhibition
and alteration ofmuscle function (89).
Once GB is in the blood, it can pene-
trate the blood-brain barrier. Cholin-
esterase inhibitors vary in their ability to
pass through this barrier, a property that
has been related to the lipid solubility of
the compound (90). Within the brains of
mice injected intramuscularly with GB,
Bajgar (91,92) observed regional differ-
ences in AChE inhibition. He concluded
that the differences in AChE inhibition
were due to regional differences in GB
penetration rather than to a differential
selectivity ofGB forAChE in specific parts
ofthe brain. Studies ofisolated, blood-per-
fused in situ dog brains administered GB
via intracarotid arterial injection (93) and
of the brains ofdogs after IV injection of
GB (88) also showed regional differences
in AChE activity. Studies in rats demon-
strated that more than 94% of apparent
GB bound to AChE in the brains 30 min
Table4. HumanRBC-ChE5,values for GB and VX administered byvarious routes
GB Reference VX Reference
Inhalation 20 mg-min/m3 (25) 5 mg-min/m3 (37)
0.004 mg/kg (82)
Percutaneous, vapor 100 mg-min/m3 (37)
Percutaneous, undiluted 0.034 mg/kg (12 hr) (72)
liquid 0.029 mg/kg (24hr) (72)
Intravenous 0.003 mg/kg (57) 0.001 mg/kg, (74)
0.0011 mg/kg (56)
Oral 0.01 mg/kg (57) 0.0023 mg/kgg (56)
after injection is actually the GB metabo-
lite isopropyl methylphosphonic acid (94).
Mechanisms other than (or in addition
to) AChE inhibition appear to be responsi-
ble for the observed toxicity of GB to the
brain. In rats, Harris et al. (95) reported
that 51% ofthe GB found in the brain was
bound to sites other thanAChE. In studies
ofspontaneous recovery from central respi-
ratory failure in guinea pigs, respiratory
recovery did not correlate with recovery of
brainstem AChE levels (44). Adams and
his colleagues concluded that the recovery
occurred through a desensitization of the
ACh receptors to the excess ACh, but it is
also possible that AChE inhibition was not
actually responsible for the initial respira-
tory failure. GB causes a number of non-
cholinergic effects in the brain, including
effects on other neurotransmitters and
enzymes. Most effects are too detailed to
discuss individually in this analysis, but all
emphasize the point that GB does much
more than simply inhibit AChE in the
brain (23,58,59,61,67,96,97.
Data on human responses to GB come
from accidental exposures and from limit-
ed studies on low doses ofGB given to vol-
unteers. In one incident of accidental
exposure to GB vapors (estimated at 0.09
mg/mi3 for an undefined duration), two
men had significantly lowered RBC-ChE
for 80-90 days (one showed depression to
19% ofbaseline activity, the other to 84%
of baseline) and extreme miosis that per-
sisted for 30-45 days, but no other signs or
symptoms of nerve agent poisoning (39).
Other accidental inhalation exposures to
GB with similar recovery times for RBC-
ChE activity and miosis were described by
Sidell (40). In one, the individual mani-
fested severe symptoms and required respi-
ratory assistance and extended hospitaliza-
tion after cleaning a GB-contaminated area
while wearing defective protective gear. In
the other case, three workers who were in
an area with a leaky GB storage container
suffered temporary symptoms, such as
transient mild respiratory distress, together
with marked miosis and RBC-ChE activity
depression. The RBC-ChE depression
required 3 months for full recovery; the
miosis (measured in the dark) recovered in
30-60 days.
Grob and Harvey (57) reported the
effects in humans of administered low
doses of GB. When either 0.003 or 0.005
mg/kg ofGB was injected directly into an
artery in the arm of one volunteer, Grob
and Harvey observed some initial local
effects (reduction in grip strength, tremors
after exercise) followed by systemic effects,
including many of the symptoms listed
earlier. These doses, which correspond to
21% and 36% ofthe estimated human IV
LD50, resulted in RBC-ChE activity reduc-
tions to 52% and 28% oforiginal activity
(i.e., depressions of 48% and 72%) and
plasma ChE activity reductions to 61%
and 42% (i.e., depressions of 39% and
58%), respectively.
After combining with a ChE molecule,
the agent-ChE complex may either sponta-
neously dissociate (resulting in reactivation
of the ChE) or "age," in which case the
agent-ChE complex becomes resistant to
reactivation by an oxime antidote. Aging is
thought to result from stabilization of the
nerve agent-ChE complex by loss of an
alkyl or alkoxy group (Fig. 3). In agree-
ment with Grob and Harvey's work (57),
Sidell and Groff(56) observed little, ifany,
spontaneous reactivation of RBC-ChE
after GB administration to volunteers.
Furthermore, the GB-ChE complex aged
at a moderate pace, with aging 50-60%
complete 5 hr after GB infusion (56).
When GB was given orally to 10 vol-
unteers, approximately 3.5 times as much
GB (in mg/kg) was needed to produce the
same degree ofplasma or RBC-ChE activi-
ty depression as previously observed with
intra-arterial injection (see Table 4) (57).
With the oral administration, Grob and
Harvey noted a narrow margin between
doses that produce mild signs and symp-
toms and those that produce moderately
severe effects. They also noted that, after
the disappearance of signs and symptoms,
an increased susceptibility (in terms oftype
and severity of responses) remains to fur-
ther GB exposure within 24 hr ofthe first
exposure. Anorexia, nausea, and chest
tightness were among the first symptoms
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Figure 3. The nerve agent-acetylcholinesterase (AChE) complex may undergo either spontaneous reacti-
vation by hydrolysis or stabilization ("aging") by loss of an alkyl or alkoxy group; stabilization proceeds at
a faster rate than hydrolysis and therefore predominates. In humans, the GB-AChE complex is 50-60%
aged by 5 hr, whereas VX ages more slowly, with only40% aged at48 hr after exposure (56).
reported; abdominal cramping, vomiting,
and diarrhea were among later effects;
miosis was not observed after oral adminis-
tration. The possibility oforal exposure of
the population to GB is remote because
GB dissipates rapidly under most environ-
mental conditions. Only when tempera-
tures are 00 or less can GB persist for a few
hours as a ground contaminant (22,98).
As mentioned previously, GB vapor is
less effective as a toxic skin penetrant than
as an inhalant. The estimated human
LCt5O (clothed, resting) for dermal toxicity
is 150 times higher than the estimated
human LCt50 for inhalation (Table 2).
Fielding (28) summarizes information
from several sources, some still classified.
Rapid evaporation from the skin is the pri-
mary factor in the relatively low dermal
toxicity ofGB; ifevaporation is prevented
(i.e., by covering the exposed skin with a
cup), the toxicity of GB increases almost
100-fold (99). Another factor limiting the
dermal toxicity is the reaction ofGB with
skin constituents, which attenuates the
amount of GB that reaches target tissues
(100). Fats such as lanolin and lard have
been shown to enhance the skin penetra-
tion of GB, probably by dissolving the
agent and by preventing evaporation (28).
Mechanical abrasion of rabbit skin in-
creased GB dermal toxicity 100-fold (101).
Fielding (28) relates a tragic incident that
illustrates the wide individual variability in
dermal sensitivity to GB. Seventeen of 18
men exposed dermally to 200 mg of GB
(12% of the estimated dermal LD50 for a
70 kg man) through two layers ofclothing
showed no signs or symptoms of GB poi-
soning; the eighteenth man died shortly
after the onset ofexposure, despite imme-
diate treatment when signs of nerve agent
poisoning appeared.
In a review ofGB toxicity, McNamara
and Leitnaker (25) state: "Absorption
through the conjunctiva causes local effects
but negligible systemic effects." Grob and
Harvey (57) instilled 0.0003 mg GB in the
eyes (conjunctival sacs) of volunteers and
noted a marked miosis that began at 10
min and slowly diminished over a period
of 60 hr. At a dose of 0.0009 mg, the
pupillary constriction that occurred was
near maximal for 72 hr and did not disap-
pear until after 90 hr. In this study, miosis
was measured in the light; other studies in
which it was measured in the dark showed
it persisted for weeks. No depression of
blood ChE activity was noted at either
dose level. In studies on GB applied to the
conjunctival sac of guinea pigs, a rapid
dose-dependent depression ofAChE activi-
ty in the iris and cornea was noted with a
lesser inhibition of AChE in the retina
(retina required 10 times the iris dose to
achieve the same AChE inhibition), but no
examination was made of RBC-ChE de-
pression or other systemic effects in the
treated guinea pigs (102). However, ocular
LD50 values are available for several animal
species that are equivalent to the LD50 val-
ues for subcutaneous injection (11). This
suggests that systemic effects are possible
with GB absorption through the conjunc-
tiva and possibly the cornea ofthe eye.
Studies ofthe retention and absorption
ofGB vapors by resting or exercising men
demonstrated that the inactive men re-
tained a higher percentage of the inhaled
GB (82). Under similar exposure condi-
tions of time and concentration, however,
the active men received a larger dose ofGB
because oftheir greater air intake.
In determining the lowest concentra-
tion of GB that produces a biological
effect, miosis provides a sensitive indicator
for nerve agent exposure in humans.
Questions, however, cloud the validity of
the estimated no effects (0.5 mg-min/m3)
concentration-time product (Ct) for miosis
by GB (Table 2). The basis for this deter-
mination by McNamara and Leitnaker
(25) is found in a report byJohns (103) of
pupil diameter response in volunteers
exposed to low atmospheric concentrations
of GB (maximum Ct = 6 mg-min/m3
where tmax = 20 min). We consider the
data insufficient to confidently predict
concentrations of GB that would cause
miosis in none of the population (no-
effects level). The Johns study (103) was
not designed to determine a no-effects
level; it is not clear how McNamara and
Leitnaker (25) derived their no-effects
value of0.5 mg-min/m3 fromJohns's data.
We consider the true no-effects level likely
to lie below 0.5 mg-min/m3. The lack of
raw data and absence of measures of vari-
ability in Johns's (103) report hinder pre-
cise reanalysis. Estimates of a human no-
effects level for VX, as discussed below,
were based in part on these for GB; the VX
estimate consequently suffers from a simi-
lar question ofreliability.
AgentVX
A contributing factor to the high toxicity
ofVX may be its preferential reaction with
AChE. Unlike the G agents, VX depresses
RBC-ChE activity significantly more than
plasma ChE in humans (56); the result is
that more VX is available to react specifi-
cally with the target enzyme, AChE. Less
VX is required than GB to reduce RBC-
ChE 50% below baseline levels in humans
by all routes of administration for which
data are available (see Table 4).
Once inside the body, VX not only
inhibits AChE activity but also reacts
directly with the ACh receptors and other
neurotransmitter receptors (68,97,104).
Rickett et al. (105) have briefly reviewed
some of the evidence for effects at the
receptor level. Although GA and GB may
react with the ACh receptor in a manner
similar to ACh itself (106), results of pre-
liminary studies suggest that VX may
counteract the effects ofACh, acting as an
open channel blocker at the neuromuscular
junction (105). The clinical significance of
these effects is doubtful, however, because
the concentrations of anticholinesterase
needed to exert effects in ionic channels in
vitroare many times the LD50 in vivo.
Two other features of VX toxicity are
worthy of mention. First, in contrast to
observations on GB, the VX-RBC-ChE
complex has been found to undergo a sig-
nificant degree ofspontaneous reactivation
in humans. In a study by Sidell and Groff
(56), spontaneous reactivation of human
RBC-ChE proceeded at a rate of about
1%/hr over the first 70 hr after IV admin-
istration ofVX.
A second feature of VX toxicity is the
lack of aging or stabilization of the agent-
ChE complex and the relative ease ofreac-
tivation ofVX-poisoned enzyme by oxime
antidotes in humans (56). By 48 hr after
exposure, no aging was observed. The VX-
ChE complex was more easily reactivated
by oxime antidote at all times up to 48 hr
after exposure (when the experiment was
terminated) than was GB-ChE.
Estimates are available for human
lethal inhalation doses of VX in both
aerosol (small particles) and vapor (gas)
phases (Table 2). Animal inhalation data
are available primarily for VX aerosol. In
most cases, only the animals' heads and
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not their total bodies were exposed, so as
to limit the skin absorption of VX. The
mouse LCt50 values for both vapor and
aerosol were obtained with total-body
exposure; in the case of VX aerosol, skin
absorption appears to contribute to the
total toxicity. The estimated human LCt5O
values are equivalent for vapor and aerosol.
However, it would probably be difficult to
achieve a high vapor concentration of VX
because of its low volatility; therefore, it is
likely that a longer exposure to VX vapor
would be necessary to achieve the same
endpoint.
It should be borne in mind that the VX
LD50 values for humans have been derived
from mathematical models, extrapolations
from animal data, and estimates from sub-
lethal experimentation in humans. Many
of the original reports in which these
human values were derived are confidential
and unavailable for open-literature review.
In general, AChE activity levels have been
used as indicators of VX toxicity in hu-
mans. However, extrapolation to LD50
estimates from AChE activity determina-
tions may have little meaning because of
the poor correlation between AChE activi-
ty and toxicity in animals and wide varia-
tions in RBC-ChE levels at which toxic
effects occurred in human studies (56,74).
Dermal absorption is a more likely
route of VX exposure than inhalation;
moreover, dermal toxicity is more likely to
occur from the absorption ofVX aerosol or
liquid than from the vapor. The LCt
estimates for dermal absorption are estab-
lished by exposure ofanimals to VX vapor
or aerosol in a special chamber in which
only the body is exposed. The animals
were often shaved, clipped, or depilated
before exposure to approximate human
skin exposure, and the wind speed within
the chamber was varied to simulate a range
ofmeteorological conditions.
Although wind speeds of 20 mph may
never be encountered in an unplanned
release ofVX, it is important to realize that
wind speed can significantly increase the
dermal toxicity of VX. A 20-mph wind
speed resulted in a 20-fold reduction in the
dog LCt5O values when compared with
tests conducted in still air (89 versus 4.6
mg-min/m3; Table 2), and the rabbit
LCt5O, when determined with an 8-mph
wind speed (8.3 mg-min/m3), was 3.4
times lower than that obtained in still air
(28 mg-min/m3) (Table 2). Another way
ofdetermining VX dermal toxicity in ani-
mals is to apply liquid VX directly to the
bare skin. The LD50 values for skin ab-
sorption are similar for monkey, pig, dog,
cat, rabbit, and mouse (Table 2).
Although the animal data summarized
in Table 2 primarily show the influence of
wind speed, other factors affecting the der-
mal LCt50 values include particle size and
degree of skin exposure (clothed or bare).
Krackow (24) calculated dermal LCt5O val-
ues for men wearing gas masks so that only
the neck, ears, hands, and wrists were
exposed to aerosol particles ranging in size
from 5 to 15 pm at wind velocities from 0
to 10 mph. Under these conditions, a
lower LCt5O (75 mg-min/m3) was estimat-
ed for the larger particles with the higher
wind velocity, while an LCt5O of 300 mg-
min/m3 was for the smaller particles at the
lowest wind speed. Other data ofKrackow
suggest that, with 10-pm particles and 20-
mph winds (or 20-pm particles and 10-
mph winds), the LCt5O might be as low as
3 10 mg-min/m.
The human dermal LCt5O values listed
in Table 2 for VX vapor are based on VX
vapor containing 2-pm particles (11).
These exposure conditions represent a
hybrid vapor/aerosol situation. Fielding
(28) considers that the dermal LCt5O values
for VX vapor and VX aerosol would be
similar under conditions of high concen-
trations in air and short exposure times.
With lower vapor concentrations, Fielding
(28) notes that "doubt has been expressed
regarding the dermal lethality ofVX vapor
to humans in view of the possibility that
the (systemic metabolism and) excretion
rate may be greater than the skin-absorp-
tion rate."
The amount ofskin surface exposed to
VX vapor or aerosol is of obvious impor-
tance. Clothing is estimated to reduce by
10-fold the dermal vapor toxicity of VX
(see Table 2). Not all body areas, however,
are equally permeable to VX. The doses of
VX necessary to cause 70% inhibition of
AChE when applied to equal areas of the
human cheek, forehead, abdomen, and
volar surface (i.e., palm side) of the fore-
arm have been estimated to be 0.0051,
0.0112, 0.0318, and 0.04 mg/kg, respec-
tively (107,108). The differences in ab-
sorption are important in evaluating stud-
ies in which the forearm is exposed and
extrapolations are made to total-body
exposure. Craig et al. (108) measured the
dermal absorption of liquid VX through
the cheeks and the forearms men at envi-
ronmental temperatures ranging from -18°
to 460C. The fraction of the applied dose
that penetrated in 3 hr ranged from 3.5%
at -18°C to 31.9% at 46°C for the cheek
and from 0.4% at +18°C to 2.9% at 46°C
for the forearm. Wide individual differ-
ences in RBC-ChE depression were seen
for both skin sites and most doses tested;
in some cases, responses ranged from 0 to
100% depression (108). The wide range of
individual responses to dermal VX expo-
sure, caused in part by differences in pene-
trability of the skin in various parts of the
body, makes the prediction of a human
dermal VX LD50 value difficult. Thus,
ranges are given rather than single values.
Because skin can act as a storage depot
for VX with movement from this depot
promoted by increased temperature, the
authors suggest that cooling of the skin
surface after dermal exposure to VX can
delay absorption until treatment is possi-
ble. Also note that immediate decontami-
nation should be a particularly effective
procedure for dermal VX exposure because
of the slowness of its skin penetration.
However, if decontamination is delayed
until 3 hr after exposure, significant lower-
ing of RBC-ChE continues after deconta-
mination (108). Specific decontamination
procedures following nerve agent exposure
can be found in Munro et al. (10).
The estimated IV LD50 for humans
(0.008 mg/kg) is similar to that deter-
mined for many animal species, with the
major exception ofthe mouse, which is less
sensitive. Low doses ofVX (0.001 mg/kg,
IV) were administered to volunteers to
assess correlation ofdose with the degree of
AChE inhibition or the presence ofclinical
signs and symptoms. By injecting VX
directly into the bloodstream, the wide dif-
ferences in individual skin absorption
observed in other studies (108) can be
bypassed. In four men who received 0.001
mg/kg VX in a 4-hr infusion, good agree-
ment was observed between the individual
percent decrease (50%) in RBC-ChE activ-
ity compared with preinfusion AChE levels
(74). (It is not possible to compare the
range ofthe absolute AChE values because
these were not given.) In another study,
reported by Sidell and Groff (56), a group
of 34 men were given doses ranging from
0.0012 to 0.0017 mg/kg in an attempt to
find an IV dose of VX that would cause
75% inhibition ofRBC-ChE levels. In this
dose range, most subjects had transient
symptoms of lightheadedness and some
experienced nausea and vomiting, with the
most prominent effects occurring 1 hr after
injection, when the RBC-ChE inhibition
was maximal. No miosis was observed,
even with 90% inhibition of RBC-ChE
activity. A dose of0.0015 mg/kg produced
75% inhibition of the baseline AChE lev-
els; linear regression analysis of the dose-
response curve gave 0.0011 mg/kg as the
estimated dose causing 50% decrease in
RBC-ChE activity (see Table 4).
There is a paucity of data on the oral
toxicity of VX, despite the fact that the
demonstrated environmental persistence of
this agent makes ingestion a relevant route
for human exposure. VX can persist on leaf
surfaces in an undegraded form, so that
animals grazing on contaminated vegeta-
tion can ingest VX. In a study on VX per-
sistence in soil after shell bursts, 46 days
after contamination sufficient VX re-
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mained to kill 4 of 10 guinea pigs fed grass
from the contaminated area [Dewey and
Fish (28,109). In sheep accidentally ex-
posed in winter to VX-contaminated vege-
tation, clinical signs of toxicity persisted
for at least 3 weeks (110). Slight ChE
depression was noted in newly introduced
sheep grazing the suspect area 2 months
after the VX release (111). The only ani-
mal oral LD50 value available for VX is 0.1
mg/kg for rats (Table 2).
In 32 human volunteers given single
oral doses ofVX in water, a dose of0.004
mg/kg caused a 70% reduction in RBC-
ChE levels (56). This oral dose is about
three times the human IV dose needed to
cause a similar level of RBC-ChE inhibi-
tion. The oral ChE 0 value calculated by
Sidell and Groff (56) from the dose-
response curve obtained in their study is
0.0023 mg/kg (see Table 4). At oral doses
ranging from 0.002 to 0.0045 mg/kg, only
a few subjects (5/32) suffered any gastroin-
testinal signs or symptoms, and there were
no changes in heart rate, blood pressure, or
pupil size in any ofthe subjects. Eating 30
min before drinking the VX solution
appeared to enhance the RBC-ChE inhibi-
tion; tap water (as compared with a 5%
dextrose solution) seemed to retard the
anti-RBC-ChE activity. In an earlier study,
volunteers were given four oral doses/day
of VX in drinking water for 7 days (con-
centration about 0.05 mg/l in four 500-ml
portions; individual daily dose of0.00143
mg/kg) (112). No signs or symptoms of
toxicity were observed although RBC-ChE
was 40% ofbaseline byday7.
Estimates have also been made for
human ICt50 either by inhalation or byskin
absorption ofVX aerosol or vapor (Table
2). The ranges in these estimates are due in
part to different test conditions (i.e., varied
particle sizes in the case ofaerosols and dif-
ferent wind velocities). Fielding (28) notes
that these ranges may also depend on what
is meant byincapacitation.
Estimates have been made for the low-
est air concentration of VX that produces
miosis, one ofthe more sensitive indices of
human exposure to the vapors of anti-
cholinesterase compounds. The estimated
ECt50 found in Table 2 for pupillary con-
striction by VX is an extrapolation from
the derived value for GB in humans (25).
To obtain the VX ECt50 for humans, the
estimated ECt5O for miosis in humans
exposed to GB was first compared with the
minimum dose ofGB that causes miosis in
rabbits, and the assumption was made that
man is twice as sensitive as the rabbit. This
factor oftwo was then applied to the con-
centration of VX that produces pupillary
constriction in rabbits to arrive at the min-
imum concentration ofVX that would be
expected to cause miosis in humans (7).
Similarly, the VX no-effects doses for mio-
sis and for tremors are based on extrapola-
tions from derived values for GB. Because
these VX estimates are used to determine
presumed safe levels for human exposure
to VX, more research is needed to deter-
mine whether these minimum and no-
effects values are credible.
The effects of acute VX exposure on
mood and mental function are similar to
those of GB. Kimura et al. (74) reported
the results ofthe first experimental human
exposures to VX. One subject became irri-
table, reported headache, spoke less clearly,
and became confused and then irrational
and agitated after receiving 0.00212 mg/kg
VX IV over 5.5 hr when whole-blood ChE
activity reached about 10% ofbaseline. Six
others received 0.001 mg/kg VX IV over
periods of 1.75-4 hr; only one subject
reported headache and discomfort. Bowers
et al. (41) reported transient depressive
effects on mental functioning and mood
(as correlated with ChE depression and
gastrointestinal symptoms) in 93 adult
male volunteers percutaneously to VX.
[Bowers et al. (41) identify the agent only
as EA-1701; Krackow (24) identifies this
code with VX.] The psychological effects
were usually seen well before the onset of
gastrointestinal symptoms in those subjects
who experienced both types ofeffects.
Sidell and Groff(56) reported a study in
which 66 volunteers received VX either IV
or orally. Doses ranged from 0.0012 to
0.0017 mg/kg IV and 0.0020 to 0.0035
mg/kg orally. The 0.0015 mg/kg IV group
suffered a significant decrement in mental
performance on a number facility test (the
higher dose groups had been pretreated with
scopolamine and were not monitored for
changes other than in RBC-ChE activity).
The effect was seen only in the first hour
after VX injection. Those receiving VX by
the oral route showed little or no indications
of CNS effects and fewer gastrointestinal
effects despite generally lower RBC-ChE
activities. Thus, the authors suggested that
the nausea and vomiting in the IV group
were probablycentrally mediated.
Comparative Toxicity of GA,
GB, and VX
The relative potency ofGA, GB, and VX
varies with the route of exposure. In-
halation or percutaneous absorption of
vapor or aerosol demonstrates that VX is
more toxic than GB, which is more toxic
than GA (i.e., VX > GB > GA). The der-
mal toxicity ranking is VX > GA > GB,
while the ranking based on estimates ofIV
toxicity is VX > GA = GB. These differ-
ences relate to varying physical, chemical,
and toxicological properties among the
nerve agents. Agent VX, for example, is
not only much less volatile than the G
agents, it is not detoxified in the skin and
combines little, if at all, with plasma
cholinesterases. Thus, VX is more readily
available to inactivate tissueAChE.
The human inhalation toxicity of GA
vapor is approximately half that of GB
(Table 2); this difference is well supported
by the animal data. GA appears to be more
toxic to the ciliary muscles ofthe eyes than
GB because constriction ofpupils occurs at
a lower concentration of GA [i.e., mini-
mum effective doses of 0.9 and 2-4 mg-
min/m3, respectively (11)]. The estimated
LD50 for GA toxicity in humans by skin
absorption is roughly equivalent to the
estimate for GB, and the human IV LD50
estimate for GA is equal to that for GB.
The equivalencies of these estimates are
not necessarily supported by the animal
data, but no discussions ofthe bases for the
human estimates are given in the source
documents (11,21).
Although GB is less toxic than VX by a
variety ofexposure routes, GB may actual-
ly be more toxic than VX at the neuromus-
cular junction. When GB or any one of
several V agents related to VX was applied
directly to the isolated rat diaphragm at the
neuromuscular junction (thereby eliminat-
ing factors such as absorption efficiencies
and attenuation differences), GB was
found to be twice as potent as the Vagents
(113). Intravenous infusion ofGA, GB, or
VX in cats at the rate ofone LD50 per 15
min demonstrated that 0.5 LD50 of GB
was sufficient to induce respiratory arrest,
whereas 1.25 and 15 LD50 doses were
needed for GA and VX, respectively (48).
These differences reflect the rapidity ofthe
toxic action ofGB compared with VX and
the somewhat higher toxicity compared
with GA.
In comparison with GB human expo-
sure estimates, VX is estimated to be
approximately twice as toxic by inhalation,
10 times as toxic by oral administration,
and approximately 170 times as toxic after
skin exposure (114). Under conditions
favorable for skin penetration, VX can be
about 1000 times as toxic as GB in rabbits
(28). The evaporation ofVX from the skin
is almost negligible, whereas GB evaporates
in a matter of minutes (see Table 1 for
comparative volatility data). Agent GB
penetrates the skin more rapidly than VX,
but VX undergoes virtually no degradation
as it slowlypenetrates the skin; thus, more
of this compound is able to reach the
bloodstream (115). Whereas GB skin pen-
etration in rabbits appeared to be complete
by 30 min (100) [with a penetration effi-
ciency ofnonevaporating GB calculated to
be only 0.04% (28)], complete penetration
by VX, with essentially 100% of the skin
dose reaching the circulatory system,
required about 4.5 hr (116). In vitro stud-
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ies suggest that VX can penetrate in unal-
tered form through the epidermis and der-
mis of the skin, penetrate through the
nerve membranes, and can accumulate
within the nerve cells (117).
A number ofinvestigators have report-
ed the distinctly slower toxic action ofVX
as compared with the G agents, as well as a
slower rate of recovery (105,118). This
delay cannot be attributed only to slower
skin penetration because a slower response
is also observed when VX is administered
intravenously (48,56). With GB there is
essentially no difference between the 15-
min and 24-hr lethal IV dose; with VX
there is an approximate twofold difference
(28). It is important, therefore, in deter-
mining LD50 and LCt5O levels for VX to
allow enough time to accurately assess the
toxicity. Although the biological basis for
this delay is not fully understood, Fielding
(28) hypothesized that the larger molecular
size (see Fig. 1) and different solubility
characteristics of VX may cause it to dif-
fuse more slowly than G agents through
tissues and cell membranes to the target
tissues.
Mixtures
Both GB and VX are stored at several of
the stockpile sites (LBAD, ANAD, PBA,
TEAD, and UMDA). While munitions
containing a given agent are placed in seg-
regated bunkers, igloos, or storage build-
ings and, likewise, ton containers are segre-
gated by agent type, the stockpile sites con-
tain limited areas of contiguous rows of
bunkers or other storage units containing
unlike agents. While the probability of an
accident such as an airplane crash into one
of these areas of adjacent storage units
resulting in release ofmore than one agent
type is extremely low, such a release is con-
sidered here for the sake ofcompleteness.
Thus, the question arises as to toxic
effects ofa GB-VX mixture ifthese agents
were simultaneously released. In the only
study found to date that addresses this
issue, GB and VX were administered
simultaneously and sequentially to mice
(119). When the agents were administered
as a mixture of 0.5 LD50 of each agent
(GB = 95 pg/kg, VX = 9 pg/kg9, the result-
ing mixture had an LD50 lower than one
LD50 of either agent alone, meaning that
the total effect was more than additive.
When a 0.5 LD50 dose ofVXwas adminis-
tered 1 hr before a 0.5 LD50 dose of GB,
brain and blood AChE were depressed less
than by sequential administration of two
0.5 LD50 doses of GB given 1 hr apart.
Thus, VX had a protective effect on blood
and brain AChE depression produced by
GB. However, when the nerve agents were
administered in reverse order (0.5 LD50 of
GB before 0.5 LD50 ofVX), blood AChE
inhibition was greater, but brain AChE
inhibition was less than that induced by
two serial 0.5 LD50 doses ofVX.
Approximately 50-fold potentiation of
toxicity with the administration of certain
combinations ofOP insecticides [EPN, 0-
ethyl 0-(4-nitrophenyl) phenylphospho-
nothioate and malathion] has been de-
scribed (120); however, with other insecti-
cide combinations [malathion and ronnel;
compound 4072 (Dermaton) and dichlor-
vos; ronnel and dichlorvos] there was no
potentiation of AChE inhibition in the
dog (121). Further investigation is needed
to quantify the possible interactions of
toxic mixtures ofnerve agents or combina-
tions of nerve agents and pesticides, espe-
cially those relevant to the CSDP.
Delayed and Persistent Effects
of Acute Nerve Agent
Exposure
Public concern has been expressed regarding
the induction oforganophosphorus-induced
delayed neuropathy (OPIDN) by the OP
nerve agents in the U. S. stockpile. Other
possible delayed or persistent effects ofcon-
cern include cardiac dysfunction, psycholog-
ical effects, and EEG abnormalities.
The OPIDN syndrome is characterized
by a delay of5-30 days, followed by some
initially mild symptoms, such as weakness,
tingling, and muscle twitching in the legs.
A flaccid paralysis eventually develops, first
in the toes and then progressing to the
hands and thighs. Depending on dose, the
paralysis is usually persistent; recovery is
generally slow and incomplete. Some
16,000 cases of OPIDN were reported in
1930-31 among individuals in the south-
ern United States who drank an illicit alco-
holic extract ("Jamaica Ginger" or "Ginger
Jake") that was contaminated with TOCP,
a weak anticholinesterase OP ester
(122,123). Thousands of others have suf-
fered from TOCP-induced OPIDN as a
consequence of ingesting contaminated
food oils (124,125). A limited number of
people have also developed delayed neu-
ropathy in response to other OP com-
pounds, mainly the OP insecticides mal-
athion, parathion (122), methamidophos
(126), mipafox, a fluorine-containing OP
(127), isophenfos (128), and probably lep-
tophos (129). Other OPs implicated
causally in human OPIDN induction are
listed in a recent review by Lotti (130) and
include dichlorvos, EPN, trichlorfon, and
trichlornat. Delayed neuropathy induction
is associated with 70-80% inhibition of a
specific protein, neuropathy target esterase
(NTE; formerly termed neurotoxic es-
terase). The function of NTE and role, if
any, in the mechanism of OPIDN induc-
tion is unknown. Recent reviews by John-
son (131), Abou-Donia and Lapadula
(132), and Lotti (130) summarize much of
what is known about NTE. Abou-Donia
and Lapadula (132 propose a mechanism
involving phosphorylation of Ca2+/cal-
modulin kinase II, increasing its activity
and causing disruptive effects on cytoskele-
tal proteins in neuronal tissue. Thus,
although NTE inhibition may be a marker
ofOPIDN-inducing potential, it may play
no role in OPIDN induction.
Human beings are one ofthe most sen-
sitive species for OPIDN induction; hens
are equivalently sensitive and have been
used widely to test chemicals for OPIDN-
inducing potential (133). To date, human
beings are known to be significantly more
sensitive than hens to OPIDN induction
by only one chemical, methamidophos
(126,130). Lotti (130) attributed this
greater human sensitivity to a higher rate
of spontaneous reactivation of methami-
dophos-inhibited human AChE, and the
availability ofassisted ventilation tQ human
beings (but not hens).
Ratios ofanticholinesterase activity and
NTE-inhibiting activity in vitro for hen
tissue (AChE I50/NTE I50) and human tis-
sue are similar (133,134). In vivo toxicity
ratios (LD50/neurotoxic dose) for the hen
correspond well with the in vitro AChE
I50/NTEI5 ratios. Thus, it is likely that in
vivo assays in hens and in vitro human and
hen enzyme activity ratios are at least qual-
itatively predictive for human OPIDN-
inducing potential (133).
Although the data are often sparse on
the other delayed health effects of nerve
agents per se, an expanding field oflitera-
ture on delayed health effects ofOPs, par-
ticularly insecticides, exists (49,66,35).
Information from this literature is includ-
ed, particularly where there are data gaps
for nerve agents.
Agent GA
OPIDN. Agent GA has not been shown to
produce OPIDN, but it appears that it
mayhave the potential to do so under con-
ditions highly unlikely for human expo-
sure. Agent GA at extremely high doses
inhibits NTE both in vitro (136) and in
vivo in antidote-protected chickens (134).
Johnson et al. (137) showed that GA pro-
duces the aged or unreactivatable form of
inhibited NTE that is often associated with
induction of OPIDN. Results of in vitro
assays ofGA potency against bovine AChE
and hen NTE suggested that doses of
100-150 times the LD50 would be neces-
sary to induce OPIDN in vivo in hens
(14). Tests of GA in antidote-protected
chickens at 120 times the subcutaneous
(SC) LD50 dose of 0.610 pmol/kg (14)
[two 6 mg/kg doses/day intramuscular
(IM); total of 12 mg/kg/day] elicited mild
neuropathic signs in one of two surviving
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hens (138). Despite this observation, neu-
ropathy was not observed in survivors of a
single dose (12 or 15 mg/kg, IM) in that
same study (138) nor in survivors of single
doses (12 mg/kg, IM) ortwo 12-mg/kgdoses
(total dose, 24 mg/kg, IM) (one surviving
hen) (13X. Willems et al. (138) concluded
that even higher doses ofGAwould be need-
ed to produce the fully developed clinical
signs of delayed peripheral neuropathy in
chickens. Henderson et al. (139) found no
effect ofGAon NTE activityin chicken with
or without atropine protection given single
IM injections of0.125 mg/kg; results of90-
day studies using 0.07 mg/kg IM 5
days/week in atropine-protected hens were
negative for behavioral or histopathologic
signs ofOPIDN. Furthermore, dosing male
and female CD rats without atropine protec-
tion at 1, 1/2, and 1/4 times the MTD
(0.1125, 0.05625, and 0.02813 mg/kg IP,
respectively) 5 days/week for 13 weekss (90-
day study) revealed no effect on brain NTE
activity (140) and no clinical evidence of
neuropathy (141). The higher two doses
used were sufficient to depress plama and
RBC-ChE activities significantly and result
in transient clinical signs of OP toxicity in
some animals (141).
It appears that GA doses many times the
LD50 maybe necessary to induce OPIDN in
humans. Ifunprotected human populations
were ever exposed to doses this great, there
would be few survivors. There are no data to
support OPIDN induction in humans at
less-than-lethal doses ofGA. Thus, OPIDN
induction is not a relevant concern for GA
exposure.
Agent GB
OPIDN. Agent GB at high doses has been
shown to cause OPIDN in chickens, a par-
ticularly sensitive species for this endpoint
(14,142-144). This effect required doses
30-60 times the chicken IM LD50
(0.025-0.05 mg/kg) (142,143) in birds pro-
tected from death by prior injection ofanti-
dotes. A review byAbou-Donia (129) docu-
ments the induction ofOPIDN by GB only
in chickens and only at supralethal doses (1
mg/kg). More recently, Crowell et al. (145)
failed to observe significant decreases in
brain, spinal cord, or lymphocyte NTE in
atropine-protected hens 24 hr after single
administration ofGB as sarin I by gavage at
1, 3.3, and 6.6 times the maximum tolerat-
ed dose (MTD) (0.61, 0.2, and 0.4 mg/kg)
or sarin II at 1, 1/2, and 1/4 the MTD
(0.28, 0.14, and 0.07 mg/kg). The positive
control, TOCP, was effective at lowering all
types of NTE. Repeated doses of GB (by
gavage at 1/3, 1/6, and 1/12 MTD for 42
days) in atropine-protected hens failed to
result in signs of OPIDN (146), despite
exposure sufficient to cause signs of acute
toxicity.
Little evidence for GB-induced neu-
ropathy has accrued from studies in mam-
mals. For example, agent GB failed to
induce OPIDN in cats either at a supra-
lethal dose, 1 mg/kg, SC, in atropine-
physostigmine-protected animals (com-
pared to the LD50 dose of 0.035 mg/kg,
SC), or at multiple low-dose exposures
adding up to the LD50 (147,148). The low
doses (0.0035 mg/kg/day for 10 days or
0.007 mg/kg/day for 5 days, SC) generated
no signs of cholinesterase poisoning. Agent
GB (sarin I) also failed to induce OPIDN
in CD rats exposed by gavage five times per
week for 13 weeks (90 days) at doses rang-
ing from 0 to 0.3 mg/kg/day (the MTD)
(149). A 15% decrease (p < 0.05) in NTE
was seen only in the high-dose female
group. Sarin II in similar experiments also
failed to induce neuropathy in rats at doses
up to the MTD, and no effects on NTE
were seen at any dose (150). It should be
noted that the rat, unlike the cat, is relative-
ly insensitive to full OPIDN induction
(130,132) and variably sensitive to
histopathological damage. A study of the
effects ofhigh (convulsive, 5 pg/kg) or mul-
tiple small-dose GB exposures of rhesus
monkeys on EEG patterns showed no dif-
ference in behavior between exposed and
control animals examined both at 24 hr and
1 year after dosing (151). No signs ofatoxia
were noted. Some primates are considered
resistant to OPIDN induction, but others
are susceptible (129).
A recent report (152) ofa small study in
eight female Swiss albino mice suggests early
changes characteristic of OPIDN induction
resulting from low-dose GB exposure. The
animals were exposed 20 min/day for 10
days, whole-body to 5 mg/m3 GB (17% of
LC50, 600 mg/m /min, for this strain). This
exposure regimen resulted in 27% inhibi-
tion ofblood AChE and 19% inhibition of
brain AChE but caused no signs of anti-
AChE toxicity. By day 14 after onset of
exposure, the mice displayed mild signs
(slight ataxia, muscle weakness of limbs,
twitching), NTE inhibition ofbrain, spinal
cord, and platelets, and light or moderate
axonal degeneration in the spinal cord.
Mipafox caused more pronounced changes
in positive control animals. At present we
know of no reports indicating that other
groups have tried to replicate these results
in this or any other mouse strain. Further
work should be done to verify these results
in view ofthe lesser sensitivity ofthe mouse
to OPIDN induction byTOCP (153).
Bidstrup et al. (127) reported that
another fluorine-containing OP, mipafox,
induced delayed neuropathy in two chem-
ists (a male and a female) after occupation-
al exposure sufficient to cause severe acute
toxic effects. A third worker who devel-
oped less severe acute symptoms failed to
exhibit OPIDN. No dose information was
presented, but substantial exposure over a
period of several days was documented.
Davies et al. (142) tested 36 alkyl OPs and
found that the 17 compounds that caused
delayed neuropathy contained fluorine.
However, the possession ofa fluorine atom
by an OP compound does not, by itself,
indicate neurotoxic potency, as a number
offluorine OP compounds have been test-
ed and found to lack such activity (144).
Although many human volunteers
(246 individuals) (144) have been exposed
to GB by a variety of routes, no reported
instances of OPIDN are known, either
from the experimental studies (144,154) or
from accidental exposures of more than
200 individuals (Leffingwell SS, personal
communication). The doses ranged from
those causing no signs and symptoms and
no detectable decrease in RBC-ChE activi-
ty to doses causing moderate or severe
signs and symptoms and RBC-ChE activi-
ty depression of as much as 90% below
normal baseline levels (57,155). Most of
the accidental GB exposures were very
mild and, while formal long-term follow-
up was not done, no employee reported
signs of OPIDN after returning to work,
nor did they report such symptoms on
subsequent contacts with the medical staff.
Six severe GB exposures are known, and
the U. S. Army Medical Research Institute
of Chemical Defense is not aware of any
evidence for OPIDN having developed in
any of those cases (Sidell FR, personal
communication).
In summary, while the possibility of a
human developing OPIDN in response to
a supralethal dose of GB cannot be ruled
out, the major concern would be immedi-
ate treatment to prevent death. There is no
evidence of GB causing OPIDN in hu-
mans, nor is there current evidence for this
effect resulting from low-dose GB exposure
(lower than those resulting in acute toxic
effects) in any species other than the
mouse.
Psychological effects. Acute exposure to
GB has been shown to cause both transient
and prolonged changes in psychological
function. Evidence is available from several
cases of accidental exposure in which the
doses are unknown but effects can be cate-
gorized as severe or moderate (56,156,
157). At least some of the persistent
changes may have resulted from brain
damage caused by GB-induced convulsions
(156). Agent GB induction of transient
depressive emotions, insomnia, excessive
dreaming, and nightmares have been
observed in volunteers in the absence of
seizure activity (155). Grob and Harvey
(57) reported similar effects, as well as
EEG changes that persisted for 4-18 days
after oral administration of GB to 10 vol-
Environmental Health Perspectives 28I III Alc 9 s
unteers for 1-4 days. Repeated doses were
sufficient to produce 85% depression of
plasma ChE activity and more than 97%
depression of RBC-ChE activity. As-
sociated physical signs and symptoms were
described as moderately severe but fell
short of convulsions. Occupationally
exposed workers exhibited similar signs
and symptoms after low-level exposures to
G agents; in some cases, effects persisted
beyond 3 days (158,159).
Sidell (71) considers that mild psycho-
logical changes resulting from nerve agent
exposure to be more common than ordi-
narily recognized and to occur even in a
small fraction of individuals experiencing
few or no other signs of exposure; effects
may persist from days to weeks. Sidell (71)
also points out that the psychological
effects can delay fitness for return to any
work requiring full cognitive function and
rapid decision-making.
That GB doses sufficient to cause acute
toxic effects may also result in long-term
psychological changes is further suggested
by a recent study of workers previously
acutely intoxicated by OP insecticides.
This study documents persistent insecti-
cide effects similar to those of nerve agent
exposure on mental function and emotion-
al state. Savage and colleagues (135) evalu-
ated 100 individuals who had experienced
1 or more documented episodes of acute
poisoning on average 9 years earlier (in at
least 80% ofthe cases byparathion, methyl
parathion, or malathion, dose unknown).
These individuals showed mild but statisti-
callysignificant deficits in intellectual abili-
ty, academic skills, abstract thinking abili-
ty, and speed and coordination on motor
skill tests in comparison to matched con-
trols. They evidenced more depression,
irritability, confusion, and tendency to
withdrawal than controls on an inventory
by relatives and perceived themselves to
have areas of difficulty with memory,
thinkingability, and use oflanguage.
Organophosphate insecticides are
sequestered in body fat and gradually
mobilized from these depots to a greater
extent than the OP nerve agents as evi-
denced by their longer time course of
recovery and need for repeated treatment
with atropine (160,161). Thus, OP insecti-
cides may be more likely than nerve agents
to cause CNS effects and to induce
changes persisting longer than those possi-
blyinduced by OP nerve agents.
EEG effects. Duffy and colleagues
reported subtle long-term changes in
human brain function after acute GB
exposure (162,163). In these studies,
exceedingly subtle changes in EEG pat-
terns and increases in rapid eye movement
(REM) sleep were observed at 1-6 years
after accidental exposure to GB sufficient
to cause acute signs and symptoms and to
lower RBC-ChE by at least 25% below
baseline. Statistically significant EEG
changes were detected only by computer
analysis in a group comparison ofexposed
workers with control subjects; trained neu-
rologists were unable to distinguish by
visual inspection between EEGs ofexposed
and unexposed individuals. Thus, the EEG
changes are not considered clinically signif-
icant. Some of the workers studied by
Duffy and colleagues (162,163) had been
studied earlier by Metcalf and Holmes
(164), who also reported on EEG, psycho-
logical, and neurological changes in per-
sons exposed to OPs including insecticides
and nerve agents. When the EEG patterns
of the exposed OP worker group were
compared with the EEGs of a control
group ofworkers who had no exposure or
access to OPs, minimal group differences
were observed, consisting mainly of in-
creased medium-voltage irregular 0 waves,
usually during drowsiness [for details of
EEG spectra differences, see Duffy et al.
(162)]. Note that, as in the study by Duffy
and colleagues (162,163), these EEG
changes were evident a year or more after
exposure-during this time the workers
had no other known OP exposure and
showed no blood ChE activity depression.
Comparing the "highly exposed" worker
group to the "minimally exposed" worker
group, Metcalf and Holmes (164) found
memory, concentration, and sleep distur-
bances, as well as subtle EEG changes (not
clinically significant) and minor motor
coordination deficits. The Metcalf and
Holmes report does not clarify whether the
GB exposures of the subjects were recent,
nor whether the persistent EEG changes
could be correlated with the observed per-
sistent psychological changes.
After the observation of EEG changes
in GB-exposed workers, a study was car-
ried out in monkeys in an attempt to sub-
stantiate these long-term EEG effects
(151). The monkeys were given either a
single dose of GB (0.005 mg/kg, IV) that
produced overt toxic signs or 10 smaller
doses (0.001 mg/kg, IM, at weekly inter-
vals) that resulted in no clinical signs. In
both the acute and subchronic exposure
groups, increases in jB activity were ob-
served in the spontaneous cortical EEG
patterns up to 1 year after exposure.
No difference in gross behavior was
observed between treated and control ani-
mals. Another important finding from this
study was that, at 1 year, there were greater
differences in the EEG patterns of the ani-
mals that received the series ofsmaller doses
(with no resulting clinical symptoms) than
in the animals receiving the single dose.
Because the total dose in the series was twice
that ofthe single dose, this suggests it is the
total amount of GB received and not the
induction ofclinical effects that determined
the degree ofEEG alteration.
In summary, clinically insignificant EEG
changes and increases in REM sleep were
observed in the worker group exposed 1-6
years earlier to levels of GB sufficient to
cause signs of toxicity. Changes were more
evident in the worker group with more
recent exposures or more than one episode of
exposure (163). Although some workers in
the same population had experienced psy-
chological changes, this studydid not address
any possible correlation between EEG
changes and psychological effects. Thus, the
meaning of subtle persistent EEG changes
after GB exposure is unclear; there may be
no meaningful behavioral or physiological
correlates. Levels ofGB exposure too low to
cause acute toxic signs and symptons have
not been tested for the ability to induce per-
sistent EEG changes.
Cardiac effects. Another potential de-
layed effect ofGB exposure is cardiac dam-
age. In a study of OP insecticide poison-
ings, certain clinical effects such as cardiac
problems often showed a delay in their
onset (160). Agent GB has been shown to
cause cardiomyopathy in rats in doses suf-
ficient to cause convulsions in many ofthe
animals (0.111-0.17 mg/kg, SC) (65).
Cardiac lesions were seen only in animals
that had convulsed with resulting brain
lesions. The cardiomyopathy may result
from CNS damage and consequent sympa-
thetic overstimulation.
AgentVX
OPIDN. Agent VX shows no potential for
inducing OPIDN (Table 5). In tests ofthe
ability of nerve agents to inhibit NTE in
vitro, VX was at least 1000-fold less active
than agent GB (14,136). Three VX-related
thiolates were also ineffective at in vitro
inhibition of NTE (14). Single IM or SC
injections of VX at 0.15 mg/kg (5 times
the LD50, IM) in atropine-protected chick-
ens produced neither inhibition of NTE
nor histological or behavioral evidence of
OPIDN (165). A structurally unrelated
fluoridothionate compound was neuro-
pathic in an acute test in the chicken at 5
mg/kg, IM (142). The ability of VX to
induce OPIDN has also been tested in
antidote-protected chickens when injected
IM at 0.04 mg/kg for 90-100 days. The
results of this subchronic exposure test
were negative; no behavioral signs or histo-
logical degeneration ofspinal cord or mus-
cles were produced, in contrast to effects
seen in the positive controls exposed to
diisopropylfluorophosphonate (DFP)
(166). In summary, there is no indication
that VX has any potential at low or high
doses for the induction of OPIDN in
human beings or other species either with
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Table 5. Results oftesting for NTE inhibition or OPIDN induction byVX and related compounds
Compound Species Route Concentration range ordose Duration Results
VX Hen NTE In vitro 10-7to 5 x 10-5 M 20 min, 370C Negative for
NTE inhibition (136)
VX Hen NTE In vitro Notspecified 30 min,370C Negligible
NTE inhibition (14)
Compound 6a Hen NTE In vitro 2.3 x 10-4 M 20 min, 370C Negligible
NTE inhibition (14)
Compound 7a Hen NTE In vitro 7.4x 10-4 M 20 min,370C Negative for
NTE inhibition (14)
Compound 8a Hen NTE In vitro 7.4 x 10-4 M 20 min, 370C Negligible
NTE inhibition (14)
VX Hen NTE IM or SC 0.15 mg/kg (5 x IM LD50) 1 injection Negative for
OPIDN induction(165)
VX Hen NTE IM 0.04 mg/kg 90-100 days Negative for
OPIDN induction(166)
Abbreviations: NTE, neuropathy target esterase; OPIDN, organsphorus-induced delayed neuropathy; IM,
intramuscular; SC, subcutaneous.
aCompounds 6, 7, and 8 were closely related thiolate analogues of VX; structures but no names given in
original source.
acute or long-term exposure.
Psychological effects and EEG changes.
Delayed or persistent psychological effects of
VX have not been reported; however, no
accidental exposures such as those with GB
are known (156), and evidence of long-
term, low-dose exposures such as the occu-
pational exposures to GB has not been
found for comparison. It is not known
whether long-term psychological effects
could be produced by acute or chronic
exposure. The potential for VX to induce
long-term EEG changes has not been tested.
Cardiaceffects.. Acute exposure to agent
VX has been shown to cause cardiac ar-
rhythmias in rats (0.012 mg/kg, SC) (167)
and-beagle dogs (0.0015, 0.003, or 0.006
mg/kg, SC; 0.25, 0.5, and 1.0 LD50,
respectively) (168) at doses too low to
cause convulsions. The arrhythmias in rats
were associated with a high incidence of
mortality. The ventricular arrhythmias
seen in beagles included a form (Torsade
de pointes, a rapid, multifocal ventricular
arrhythmia) that is rare but characteristic
of cardiac abnormalities seen in OP insec-
ticide-poisoned humans. Histological
examination to evaluate the induction of
cardiomyopathy was not performed in
these studies. Whether VX has the poten-
tial to cause fatal arrhythmias in humans or
long-term cardiac damage at high doses is
not known, although cardiac arrhythmias
were not observed in experimental studies
on volunteers reported above (56,74).
Chronic Toxicity,
Genotoxicity, Carcinogenicity,
Teratogenicity, and
Reproductive Toxicity
Agent GA
Information on the toxicological effects of
GA is limited in comparison to that for
GB and VX, but a number ofstudies have
been sponsored by the U.S. Army Medical
Bioengineering Research and Development
Laboratory; results are summarized in
Table 6. These include studies of sub-
chronic toxicity in rats, teratogenesis test-
ing in rabbits, and several types of short-
term genotoxicity.
Subchronic toxicity. Male and female
CD rats were given GA without atropine
protection at 0.1 125, 0.05625, 0.02813,
and 0 mg/kg/day, 5 days/week, for 13
weeks (90-day study). Plasma and RBC-
ChE activities were significantly depressed
in the two higher dose groups. No evi-
dence of systemic toxicity was observed at
any dose other than the effects on
cholinesterase activity. Clinical chemistry
results and hitopathology examinations
revealed no other toxicity (140,141).
Genotoxicity. In tests of mutagenicity,
GA was weakly mutagenic in the mouse
lymphoma assay and in the Ames test
using S. typhimurium (170). Agent GA
induced sister chromatid exchanges (SCE)
in vitro in mouse cells but not in vivo in
mice (170). Agent GA failed to induce
unscheduled DNA synthesis (UDS) in rat
hepatocytes and, in fact, depressed UDS
with no evidence of cytotoxicity (170).
Wilson et al. (170) concluded that GA is a
weakly active mutagen.
Teratogenicity. New Zealand white rab-
bits were used to test GA for teratogenic
activity and fetotoxicity. GA was adminis-
tered SC at 0.1125, 0.05625, 0.02813
mg/kg on days 6-19 of gestation. The
results were negative for teratogenic activity,
and no fetal toxicity ofany kind was seen at
doses below those causing maternal toxicity
(Bucci TJ, personal communication).
Agent GB
Chronic andsubchronic toxicity. Weimer et
al. (169) exposed beagle dogs, Sprague-
Dawley/Wistar rats, ICR Swiss mice, and
tumor-sensitive Fischer 344 rats and strain
A mice to low concentrations (0.001 and
0.0001 mg/mi3) of airborne GB for 6
hr/day, 5 days/week for 4-52 weeks.
Animals were observed daily for toxic
signs; blood chemistry was monitored
monthly in the dogs and at the time of
euthanasia of rodents; gross and micro-
scopic examination of tissue samples from
all major organ systems was performed;
body weights were monitored throughout
the exposure period and body and organ
weights for heart, lung, liver, kidney, and
testes or ovary were recorded at necropsy.
Cardiovascular function was monitored in
the dogs. No evidence ofacute or chronic
toxicity was found at these low intermit-
tent exposure levels. Blood activity of
RBC-ChE was not depressed in any species
at either GB concentration.
Bucci and Parker (149,150) reported
the results ofsubchronic toxicity testing in
which male and female CD rats were
exposed to GB together with the stabilizers
at the concentrations used in unitary
weapons systems [tributylamine (GB type I
or sarin I) and diisopropylcarbodiimide
(GB type II or sarin II)]. The rats were
administered GB at 0.3, 0.15, and 0.075
mg/kg by gavage 5 days/week for 13
weeks. Body weights were monitored
throughout the study; blood was drawn at
1, 3, and 7 weeks and at euthanasia for
hematology and clinical chemistry mea-
sures. At necropsy, gross and histopatho-
logical examination of 144 tissues and all
lesions was performed. Although plasma
and RBC-ChE activities were significantly
depressed at all dose levels, investigators
saw no evidence ofhematologic abnormali-
ties; they noted no liver, kidney, or muscle
damage, nor effects on bodyweight gain or
organ weight. Neither form of GB was
associated with any type of neoplastic or
nonneoplastic lesion except for infrequent
evidence ofsarin I-induced cerebral necro-
sis. This effect was not related to dose.
Carcinogenicity andgenotoxicity. In the
studies by Weimer et al. (169), groups of
each rodent strain were held for an addi-
tional 6 months for observation ofcarcino-
genicity. No increase in tumors was detect-
ed in either the tumor-sensitive rodent
strain or any other test animals in response
to 6 hr/day, 5 days/week exposure for up
to 52 weeks. Although the results suggest
that GB is not carcinogenic, the low doses
and less-than-lifetime exposure and obser-
vation period preclude definitive interpre-
tation ofthe study.
Negative results in genotoxicity studies
of GB as summarized in Table 6 support
the likelihood that GB is not carcinogenic.
Agent GB did not induce mutations in the
Ames test (171) nor in mouse lymphoma
cells (171); it failed to induce SCE (174)
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Table6. Results ofgenotoxicity, carcinogenicity, and othertoxicologicaltesting ofthe nerve agents GA, GB,andVX
GA GB VX
Effect/test Resulta Reference/comments Result Reference/comments Result Reference/comments
Carcinogenicity
Rat
Mouse
Genotoxicity
S. typhimuirium
(Ames)b
Saccharomyces
cerevisiaeb
Mouse lymphoma
mutations
Sisterchromatid
exchange
Unscheduled DNA
synthesis
D. melanogaster
(sex-linked recessive
lethaltest)
Teratogenicity
Sheep
Rabbit
(169; results negative
buttestnotdefinitive;
lowdose (0.0001-0.001
mg/mi3) exposure up
to 52weeks
W+ ((168);0.2-200
mg/plate
W+ ((170);tested at5 con-
centrations (0.01-0.025
mg/ml) with activation;
tested at4 concentra-
tions (0.01-0.1 mg/ml)
withoutS-9activation
W+ in (170); 0-0.2 mg/mlwith
vitro andwithoutactivation;
tested in vivo at0.7
mg/kg IP
- (170);tested at4 con-
centrations (0.025-0.2
mg/mlwithoutactivation
(BucciT, personal communi-
cation)
Rat
(171);0.0002-0.2 mg/
100 pl;type I and 11
tested
(171);0.05,0.1,0.2
mg/ml
(172);tested in 5strains
at2.7x 10-9-1.093 mg/
plate
(173);tested in 5strains
at0.00001-0.01 mg/ml
(173); 0.025-0.1 mg/ml
(173);tested at6con-
centrations,0.001-0.1 mg/ml
- Typelandll
testedC;((174); 1.4x
10-3M
Type landll
tested;(173);3.0x
10-4to2.4x 10'3Md
(176)f
Embryotoxicity
Rat
Chick
Behavioraltoxicity
Rat
Reproductive effects
Sheep(1 generation,
female)
Rat(3generations)
Rat(dominantlethal)
Subchronic effects
Rat(male andfemale,
90days)
(179); inhalation ex-
posure,0.001 or0.0001
mg/mi3for 10months
(179);inhalation ex-
posure,0.001 or0.0001
mg/m3for 10months
(140,141);tested at0.1125,
0.05625, and 0.02813 mg/kg/day
IPwithout atropine
(149), sarin l;(150)
sarin 11h
(172);5x106and 0.004mg/mi3
(111); accidental
exposure
(173);0.00025-0.004
mg/kg SC, gd 6-19
(173);0.00025-0.004
mg/kg SC,gd6-15
(177)9
(177)9
(178); repeated doses
of0.005mg/kg SC at
varying periods of
pregnancy
(111); accidental ex-
posure
(173);0.00025-0.004mg/
kgSC,gd6-15
(173);0.00025-0.004 mg/
kg SC,gd6-15
(173);0.00025-0.004
mg/kg SC 5days/week
for13weeks
+
Abbreviations: gd,gestation day;SC,subcutaneous; IP,intraperitoneal.
VW+,weaklypositive.
bTestedwith andwithout activation.
'With stabilizers; type 1,tributylamine;tJpe1i,diisopropylcarbodiimide.
dTested at leastthreetimes at2.4 x 10- , added as20% of culture medium. GB I and 11 inhibited unscheduled DNA synthesis, indicating GB may inhibit DNA repair and allow per-
manentencoding ofmutations, oritmayprotectDNAfrom damage.
"GAgiven SC0.125,0.05625, and0.02813mg/kg/dayforgd 6-19 in rabbits.
tType I and 11tested byoral administration at0.1-0.38mg/kg/dayforgd6-15 in rats and at0.005-0.015 mg/kg/dayforgd 6-19in rabbits.
9Pregnant ratreceived single 0.01 mg/kg SC dose orrepeated0.005mg/kg SC doses,yielding reduced bodyweightofpups. Embryolethalityobserved in chicken eggsinjected with
0.032mg/egg;embryotoxicity observed at0.03mg/ratinvitro. hCD ratsgiven sarin I at0.0.075,0.15, or0.3mg/kg/day(0.3mg/kg/dayis maximumtolerated dose) 5days/weekfor90daysbygavage. Sarin II wastested usingthe same design.
Volume 102, Number 1, January 1994 31-.
or DNA repair as indicated by UDS (175).
Like GA, GB actually inhibited UDS
(175). It is not known whether this inhibi-
tion reflects an ability of G-agent metabo-
lites to scavenge free radicals and thus
reduce DNA damage resulting in decreased
need for repair. Alternatively, DNA repair
capacity may be blocked by the agents with
the result that permanent mutations could
be produced (180).
Teratogenicity and reproductive toxicity.
Tests for teratogenic effects of GB in the
rabbit and rat were negative (176) (Table
6). Agent GB as sarin I and sarin II was
tested via oral exposure in pregnant New
Zealand White rabbits and CD rats. The
number and status of fetal implants, indi-
vidual fetal weights, and fetal malforma-
tions were evaluated; no evidence ofdevel-
opmental toxicity in the first 20 days of
pregnancy was seen in either species, even
at doses of GB that resulted in maternal
toxicity or mortality.
Definitive tests of the effects of GB on
reproduction have not been performed, but
some data are available from a chronic
exposure study of low levels of GB in rats.
Denk (179) [as reviewed by Weimer et al.
(169)] reported that no dominant lethal
mutations or adverse effects on reproductive
performance occurred in rats through three
generations after exposure for 10 months to
airborne GB at concentrations of 0.001 or
0.0001 mg/mi3 (see Table 6). These levels
were so low that no overt signs of toxicity
were produced. Another study evaluated
testicular atrophy in Fischer rats after a 6-
month exposure via SC or intraperitoneal
injections of low doses of GB; no differ-
ences were found between treated and non-
treated animals (181). Weimer et al. (169)
reported no reproductive effects of long-
term GB inhalation on any group of mice
or rats except for the Fischer rats, which
exhibited an increased incidence of testicu-
lar atrophy, a condition to which this strain
is genetically susceptible. It was noted that
this group of Fischer rats had undergone
heat stress during the experiment. A follow-
up study ofunstressed Fischer rats exposed
to the same concentrations (0, 0.01, and
0.0001 mg/mi3) for 12 or 24 weeks showed
no testicular atrophy. The investigators con-
cluded that the increase in testicular atro-
phy in the first experiment was due solely to
heat stress during several weeks ofthe expo-
sure period.
AgentVX
Chronic and subchronic toxicity. Goldman,
et al. (173) reported the results ofexposing
male and female Sprague-Dawley rats to
VX (0.00025, 0.001, or 0.004 mg/kg, SC)
daily, 5 days/week, for 30, 60 and 90 days.
Blood was assayed for RBC-ChE and plas-
ma ChE activity, and a standard battery of
clinical chemistry tests was performed. At
60 and 90 days, creatinine phosphokinase
activity, an index of muscular injury, was
also determined. Urine was collected for
analysis duringweeks 8 and 12 ofthe study.
Body and organ weights were recorded and
histopathological examination was per-
formed on tissues. Hematological parame-
ters were observed in a separate group of
male and female rats exposed identically to
VX in the first generation ofa three-genera-
tion reproduction study (173).
RBC-ChE activity was significantly
depressed in male and female rats at all VX
doses for 30, 60, and 90 days. Plasma ChE
was significantly depressed in both genders
of rats given 0.001 mg/kg VX for 30 days
and in both genders of the high-dose
group at all exposure periods.
A slight decrease in body weight was
observed in the high-dose group, but no
consistent effects on organ weights were
seen that could be ascribed to VX expo-
sure. No dose-related changes were report-
ed in clinical chemistry or urinalysis para-
meters. No histopathologic lesions were
reported. Overall, the authors concluded
that VX exposure sufficient to significantly
depress RBC-ChE activity produced no
subchronic toxic effects. No studies of
long-term (chronic) VX exposure have
been reported.
Carcinogenicity. As with the other nerve
agents, the majority of animal studies on
VX have dealt with the acute toxicity of
this chemical agent. We have found no
reports of carcinogenesis studies with VX.
McNamara et al. (32 reported that there
was no association of increased cancer in
personnel working daily with VX; howev-
er, as with the other nerve agents, defini-
tive studies on the carcinogenic potential
ofVX are lacking.
Genotoxicity. The potential of VX to
cause genetic effects has been addressed in
several studies supported by the U.S. Army
Medical Bioengineering Research and
Development Laboratory (172,173) (see
Table 6). These studies include mutagenic-
ity in bacteria (S. typhimurium, Ames
assay), yeast (Saccharomyces cerevisiae),
fruitflies (Drosophila melanogaster), and in
a mammalian cell line (mouse lymphoma
L5178Y). In the bacteria and yeast studies,
VX was tested with and without metabolic
enzyme activation to determine if VX
metabolites might be mutagenic. The
range of concentrations in the Ames assay
included concentrations (1.093 mg/plate)
that corresponded to approximately
40,000 times the estimated IV LD50 for
humans (172). Results were negative in
both the Ames assay (172,173) and the S.
cerevisiae assays (173). In the Drosophila
sex-linked, recessive lethal mutation test,
only one mutation was observed at the
higher VX concentration (0.004 mg/mr3),
for a mutation percentage of 0.5% (172).
A repeat test at the same concentration
yielded no mutations. Thus, results were
also negative for VX in this mutagenicity
assay.
The fourth assay for mutagenic activity
involved the use ofmouse lymphoma cells,
which may provide better health risk esti-
mates for humans than tests using bacteria
or yeast. Again, in this assay, VXwas tested
with and without metabolic activation. At
lower concentrations (0.001-0.02 mg/ml),
there was no statistically significant in-
crease in the mutation frequency; at the
higher test concentrations (0.02-0.1
mg/ml), there was a small but statistically
significant increase in the number of
mutants that appeared to be related to dose
but not to activation (173). Compared
with controls, this increase in mutations
was less than the twofold increase set as a
criterion for a positive mutagen (182,183);
thus VX was considered by the authors to
be a nonmutagen. Agent VX also gave neg-
ative results in the SCE assay, which tests
for chromosomal damage rather than
mutations.
Teratogenicity. Data on the potential of
VX to affect fetal development (teratogene-
sis) come from the accidental exposure of
sheep to lethal concentrations of VX and
from controlled studies in rats and rabbits
(see Table 6). Van Kampen et al. (111)
reported studies on 79 surviving ewes in an
accidental 1968 VX exposure in Skull
Valley, Utah, in which 4500 of the 6300
affected sheep died or were killed. The
dose that the exposed pregnant ewes
received is not known, and the dose given
another group of purposely exposed preg-
nant ewes is classified, making it difficult
to evaluate this study. The accidentally
exposed animals demonstrated clinical
signs of toxicity; their RBC-ChE activities
were depressed for up to 4 months after
the initial intoxication, suggesting signifi-
cant VX exposure. Under the conditions of
both accidental and intentional exposure,
no evidence ofanysignificant developmen-
tal effects were noted in the offspring of
the ewes.
The teratogenic potential ofVX in rats
and rabbits was tested by SC injection of
0.00025 to 0.004 mg/kg/day on gestation-
al days 6 through 15 in rats and days 6
through 19 in rabbits. The pregnant ani-
mals were killed on day 20; the fetuses
were removed and examined for body
weight and for skeletal and organ abnor-
malities. Results of the studies in rats
showed no statistically significant relation-
ship between the dose of VX and any of
the parameters studied (173). Results of
the teratogenic studies in rabbits were also
negative.
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A preliminary study (177) suggested
embryotoxicity of VX to rat fetuses after
0.03 mg SC doses to the mother and
embryolethality to chick embryos at 0.032
mg/egg. Another preliminary study (178)
suggested that VX may exert behavioral
toxicity effects on the rat fetus after repeat-
ed SC doses of 0.005 mg/kg at varying
times during fetal development. These
results indicate that further study may be
warranted.
Reproductive toxicity. Information to
date suggests that neither acute nor chronic
VX exposure has deleterious effects on
reproductive potential. One data set comes
from the 1968 Skull Valley incident of
acute accidental exposure of sheep to
unknown levels ofVX (111). The exposed
ewes were evaluated for their reproductive
capacity by breeding them 5-6 months
after exposure. Although the dose of VX
received by the ewes is unknown, it was
sufficient to cause signs of acute-toxicity.
No effects on reproductive capacity were
found in these animals. The results of a
three-generation assay for reproductive
potential were reported to be negative in
Sprague-Dawley rats (171 ) (Table 6). The
doses of VX (0.00025-0.004 mg/kg, SC)
were administered for 5 days per week for
21-25 weeks in the F0 generation and for
24-27 weeks in the F1 generation.
Implications for Public
Protection
Several aspects of nerve agent physico-
chemical characteristics and toxicity have
ramifications of particular importance in
planning for public protection during con-
tinued storage and the active phase of the
Chemical Stockpile Disposal Program. In
view ofits volatility, GB mainly constitutes
an inhalation hazard. It would be expected
to disperse more widely than the more
dense and less volatile VX. However, all
nerve agents are readily adsorbed into
porous media such as wood, masonry, plas-
tic, painted surfaces, and fabrics, from
which they may outgas over varying peri-
ods of time (98). Thus, all nerve agents,
but especially VX, may persist in common
building materials and on agricultural
crops, posing dermal and inhalation expo-
sure hazards (18). Nondestructive deconta-
mination methods are currently unavail-
able for porous surfaces and materials
(184).
Agent control limits that are protective
in terms ofchronic inhalation exposure of
both public and occupational populations
are presented in Table 7 (185). Work is
underway to develop equivalent control
limits for drinking water and food items;
currently, no such limits exist for porous
surfaces (186). Existing technology is ade-
quate to monitor low air concentrations to
ensure compliance with atmospheric con-
trol limits, but further development is
needed to detect comparably low levels in
water and foodstuffs.
Even mild to moderate nerve agent
exposures may produce mental and emo-
tional effects that, together with effects
such as nausea, may have a pronounced
impact on public response to emergency
warnings. The implications for an exposed
civilian population include possible confu-
sion, inability to follow directions provided
in conjunction with public warnings from
emergency personnel, inability or en-
hanced unwillingness to cooperate with
authorities in the event of an evacuation
notice (e.g., inability to drive), and limited
ability to cooperate during decontamina-
tion and treatment procedures. Thus, early
warning systems are of singular impor-
tance, as well as prior education of the
public in adequate response measures.
Likewise, even mild or moderate expo-
sures to emergency responders may render
them mentally unable to return to duty for
an extended time after decontamination
and treatment result in the cessation of
physical symptoms (29,71). In any case,
responders should not return to any duty
for which there is potential for reexposure
to an anti-ChE agent before RBC-ChE
activity returns to 80% or more ofindivid-
ual baseline nor before having been asymp-
tomatic for at least 7 days (18/). Thus,
self-contamination in the course of emer-
gency response activities such as casualty
decontamination and treatment must be
stringently avoided.
Conclusions
The overreaching concern with regard to
nerve agent exposure is the extraordinarily
high acute toxicity of these substances.
These agents were designed to produce
rapid incapacitation or death at exceeding-
ly low doses. Inability to perform complex
tasks or tasks requiring good vision (espe-
cially night vision) can result from low to
moderate nerve agent doses. Such incapaci-
tation may be a consequence ofpsycholog-
ical effects alone or in combination with
gastrointestinal, ocular, or respiratory
effects and could have a significant nega-
tive impact on a population's ability to
respond to emergency warnings and in-
structions.
The congressional mandate to destroy
Table 7. Atmospheric control limits recommend-
ed by the Department of Health and Human Ser-
vices for nerve agents (185)
Agent
GA, GB
vx
General population
(72-hrTWA), mg/mi3
3 x 1O6
3 x 1O6
Workplace
(8-hrTWA), mg/m3
1 x 10
1 xlO
TWA,time-weighted average.
U. S. stockpiles ofunitary chemical warfare
agents by the end of this decade was the
stimulus for gathering and analyzing the
widely scattered literature on the toxicity
ofthe stockpiled warfare agents as summa-
rized here and, to some extent, in other
reviews. The U. S. Army Chemical Stock-
pile Disposal Program (CSDP) is currently
designed to carry out on-site, high-temper-
ature incineration of organophosphate
nerve agents stored in bulk or incorporated
into munitions. The potential for an inad-
vertent release with off-site consequences is
considered exceedingly small (probabilities
of 10-4 to 10-10for individual incidents)
during continued storage or on-site stock-
pile destruction. The continued storage
option is estimated to entail greater risks of
fatalities than on-site disposal. The poten-
tial for low-probability but high-conse-
quence releases has raised public concern
in the vicinity of the stockpile sites and is
resulting in an extensive upgrading of
emergency preparedness in the civilian sec-
tor in advance of the CSDP. This analysis
was prepared to assist the medical and
emergency planning communities and to
address various issues emerging as concerns
in the course ofpublic participation in the
planning process.
The nerve agents ofprimary concern in
the unitary stockpile are GB (sarin) and VX;
GA (tabun) is present in a small quantity at
only one location in the United States
(Tooele Army Depot in Utah). Other states
hosting or immediately adjacent to sites
where nerve agents are stored include
Alabama, Arkansas, Illinois, Indiana, Ken-
tucky, Oregon, andWashington.
Marked differences in the volatility of
the nerve agents result in significant differ-
ences in the potential geographic area
affected by an inadvertent release, in persis-
tence in the environment, and in the likely
route ofhuman exposure. Agent VX, being
less volatile than GA and GB, would be
expected to disperse less widely but to be
more persistent and to present more of a
contact hazard and potential ingestion haz-
ard from contaminated agricultural prod-
ucts. Degassing of VX from porous sur-
faces (e.g., building materials) may pose
problems of detection and decontamina-
tion before reentry can be determined to
be safe. Agents GA and GB are primarily
inhalation hazards, tend to disperse rapid-
ly, and present little contact or ingestion
hazard.
Agents GB and VX are both present at
five sites (Table 1), raising concerns about
potential interactions in the highly unlikely
event that a combined release might occur.
Limited experimental work with GB and
VX plus evidence from OP insecticide
research indicates potential for either syn-
ergism or antagonism, depending on
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whether exposure is simultaneous or se-
quential, and ifsequential, on the order of
exposure.
Organophosphate nerve agents are
highly toxic by all routes of exposure.
Their generally accepted principal toxic
mechanism is the inhibition of acetyl-
cholinesterase, although other mechanisms
ofaction also appear to contribute to their
toxicity. For example, experimental evi-
dence implicates a role for excitatory
amino acid receptors in nerve agent-
induced convulsions and brain damage.
Significant individual variations in sensi-
tivity exist, probably due in part to varia-
tions in levels of endogenous RBC-ChE
and other circulating cholinesterases as
well as body fat depots. The estimates of
human toxicity indices presented in Table
2 are based partially on animal data from
rodent species that have protective en-
zymes such as carboxylesterase which
humans lack. Thus, the estimates must be
viewed with caution as humans may be
more sensitive than some ofthe species on
which LD values and other toxicity
indices are based. Where human data were
used in combination with animal data,
they were based on experiments with
young, healthy, adult male military volun-
teers. These volunteers are clearly not rep-
resentative of the general population.
Special populations, such as infants, may
be more sensitive.
Tests of agent VX summarized in
Table 5 demonstrate no potential to
induce delayed neuropathy in any species.
Agents GA and, to a somewhat greater
extent, GB, have limited potential to
induce OPIDN, based on studies in anti-
dote-protected chickens exposed to supra-
lethal doses. From these studies, it appears
that OPIDN induction would be possible
only at GA or GB doses that would be
lethal to unprotected humans. One as-yet
unverified small low-dose inhalation study
in mice resulted in NTE inhibition, signs
of ataxia, and histologically demonstrable
axonal damage suggestive of OPIDN
induction. No human exposures, experi-
mental or accidental, have resulted in
OPIDN induction.
Moderate or greater human exposures
to GB have been associated in some indi-
viduals with transient difficulty in concen-
tration, anxiety, and depression for days or
weeks after exposure. Occupational expo-
sures have been associated with subtle
EEG changes of undefined significance.
Animal studies suggest that cardiac toxici-
ty may be associated with severe acute
nerve agent exposure, but no conclusive
evidence for effects have been observed in
humans.
Although definitive lifetime carcino-
genicity bioassay experimentshave not
been conducted with the nerve agents, no
indication of carcinogenicity has been
obtained from long-term low-dose studies
of GB in several species. Genotoxicity
screening tests were negative for GB and
VX, while GA studies indicated only weak
genotoxic potential in certain in vitro
assays. That these compounds show little
or no genotoxicity suggests that they are
unlikely to be carcinogenic. Evidence to
date suggests that the nerve agents are not
teratogenic, nor do they have deleterious
effects on reproductive function.
The rapid action of the nerve agents
requires immediate decontamination and
initiation of treatment, especially in cases
ofsevere exposure. In some cases, continu-
ous monitoring and repeated administra-
tion of antidotes as symptoms indicate
may also be needed. In severe exposures,
other supportive measures such as artificial
ventilation will be necessary. Multiple
cases of nerve agent poisoning could
severely tax local medical capabilities,
especially given the need for simultaneous
decontamination and treatment by per-
sonnel wearing protective clothing and
using somewhat cumbersome procedures
to avoid self-contamination. A remote
(probability ranging from 1 in 10-4 1 to 1
in 10-10) possibility exists of inadvertent
off-site agent contamination during stor-
age or the CSDP. A possibility also exists
for civilian exposure resulting from acci-
dental disturbance ofnonstockpile sites or
OP agent use by terrorists. Such contin-
gencies require that both first responders
and other medical personnel be well versed
in the range of acute toxic manifestations
of nerve agent exposure and appropriate
treatment procedures.
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